CITATION REPORT List of articles citing

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

DOI: 10.1128/iai.66.11.5224-5231.1998 Infection and Immunity, 1998, 66, 5224-31.

Source: https://exaly.com/paper-pdf/29910563/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper I	F	Citations
1279	IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. 1999 , 276, G1461-72		89
1278	Intestinal stasis associated bowel inflammation. 1999 , 5, 518-521		6
1277	Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. 1999 , 11, 648-56		384
1276	Interferon-gamma (IFN-gamma) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). 1999 , 117, 469-75		24
1275	COX-2: promoting tolerance. 1999 , 5, 867-8		21
1274	Linking innate and adaptive immunity. 1999 , 5, 868-70		69
1273	Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. 1999, 169, 195-207		135
1272	Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. 1999 , 116, 1107-14		636
1271	Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. 1999 , 116, 310-9		108
1270	Insights from mouse models of colitis. 2000 , 67, 267-78		109
1269	Bibliography current world literature. 2000 , 16, B57-99		
1268	Heritable Susceptibility for Colitis in Mice Induced by IL-10 Deficiency. 2000 , 6, 290-302		54
1267	Complementary and alternative medicine and gastrointestinal diseases. 2000 , 16, 188-96		11
1266	Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. 2000 , 3, 191-5		16
1265	Heritable susceptibility for colitis in mice induced by IL-10 deficiency. 2000 , 6, 290-302		61
1264	Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. 2000 , 2, 1343-51		140
1263	Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. 2000 , 15, 144-60		113

1262	Immunomodulation of Crohn's Disease. 2000 , 2, 150-66	6
1261	Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. 2000 , 14, 521-39	170
1260	Identification of genes involved in mucosal defense and inflammation associated with normal enteric bacteria. 2000 , 279, G492-9	47
1259	Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. 2000 , 278, G734-43	65
1258	Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. 2000 , 278, G829-33	165
1257	Systemic activation and antigen-driven oligoclonal expansion of T cells in a mouse model of colitis. 2000 , 164, 2797-806	52
1256	Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. <i>Infection and Immunity</i> , 2000 , 68, 5107-13	108
1255	Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. 2000 , 165, 2173-82	78
1254	Manipulation of cytokines in the management of patients with inflammatory bowel disease. 2000 , 32, 552-60	37
1253	Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. 2000 , 31, 453-7	286
1252	Staphylococcal enterotoxin B stimulates expansion of autoreactive T cells that induce apoptosis in intestinal epithelial cells: regulation of autoreactive responses by IL-10. 2000 , 164, 2994-3001	26
1251	Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. 2000 , 289, 1352-5	1139
1250	The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. 2000 , 54, 615-40	453
1249	Expression of IL-10 receptors on epithelial cells from the murine small and large intestine. 2000 , 12, 133-9	79
1248	The development of animal models of inflammatory bowel disease. 2000 , 19, 77-90	9
1247	Invited review: Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. 2000 , 6, 205-214	17
1246	Claudins regulate the intestinal barrier in response to immune mediators. 2000 , 118, 1001-11	338
1245	Necrotizing enterocolitis and hematopoietic cytokines. 2000 , 27, 697-716	17

1244	Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy. 2000 , 119, 1781-3	21
1243	Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. 2000 , 118, 1094-105	194
1242	Probiotics and inflammatory bowel diseases. 2000 , 95, S19-21	114
1241	Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. 2001 , 120, 900-13	118
1240	Probiotic bacteria enhance murine and human intestinal epithelial barrier function. 2001 , 121, 580-91	837
1239	Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. 2001 , 158, 1101-9	82
1238	Commensal host-bacterial relationships in the gut. 2001 , 292, 1115-8	1698
1237	Regulation of experimental mucosal inflammation. 2001 , 59, 244-7	12
1236	Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. 2001 , 281, G764-78	142
1235	Crohn-like enteritis presenting as hypoglycemia in a patient with glycogen storage disease type 1b, treated with granulocyte colony-stimulating factor and splenectomy. 2001 , 32, 197-200	2
1234	Induction of mucosal immune responses by bacteria and bacterial components. 2001 , 17, 555-61	21
1233	Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on Acetic Acid-Induced Colitis in Rats. 2001 , 36, 630-635	23
1232	Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. 2001, 50, 387-95	125
1231	Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. 2001 , 131, 2034-9	111
1230	Review article: the immunoregulatory cytokine interleukin-10a therapy for Crohn's disease?. 2001 , 15, 1709-16	39
1229	Interleukin-10 and the interleukin-10 receptor. 2001 , 19, 683-765	5038
1228	Microbiological and immunological strategies for treatment of inflammatory bowel disease. 2001 , 3, 1157-66	26
1227	Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. 2001 , 7, 136-45	117

1226	Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. 2001 , 2, 45-63		8
1225	The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. 2001 , 166, 7625-33		50
1224	Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. <i>Infection and Immunity</i> , 2001 , 69, 2277-85	3.7	269
1223	Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. <i>Infection and Immunity</i> , 2001 , 69, 4232-41	3.7	119
1222	CD4 T cells monospecific to ovalbumin produced by Escherichia coli can induce colitis upon transfer to BALB/c and SCID mice. 2001 , 13, 1561-70		23
1221	Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. <i>Infection and Immunity</i> , 2001 , 69, 6044-54	3.7	56
1220	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. 2001 , 96, 2691-9		171
1219	Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. 2002 , 196, 505-15		273
1218	The genetic jigsaw of inflammatory bowel disease. 2002 , 50 Suppl 3, III31-6		42
1217	Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. 2002 , 169, 6112-9		177
1216	Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. 2002 , 97, 2000-4		299
1215	Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. 2002 , 66, 246-56		79
1214	IL-15-dependent activation-induced cell death-resistant Th1 type CD8 alpha beta+NK1.1+ T cells for the development of small intestinal inflammation. 2002 , 169, 460-8		76
1213	Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. 2002 , 169, 5308-14		75
1212	Microflora reactive IL-10 producing regulatory T cells are present in the colon of IL-2 deficient mice but lack efficacious inhibition of IFN-gamma and TNF-alpha production. 2002 , 50, 170-9		26
1211	Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. 2002 , 51, 842-8		73
12 10	Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease. 2002 , 9, 54-9		38
1209	Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. <i>Infection and Immunity</i> , 2002 , 70, 6567-75	3.7	105

1208	A model for dextran sodium sulfate (DSS)-induced mouse colitis: bacterial degradation of DSS does not occur after incubation with mouse cecal contents. 2002 , 51, 203-6	10
1207	Role of mucins in inflammatory bowel disease: important lessons from experimental models. 2002 , 14, 757-65	106
1206	Molecular methods for exploring the intestinal ecosystem. 2002 , 87, S199-S201	33
1205	Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. 2002 , 160, 2253-7	247
1204	Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. 2002 , 160, 739-51	125
1203	The immunology of mucosal models of inflammation. 2002 , 20, 495-549	1112
1202	Genetics of colitis susceptibility in IL-10-deficient mice: backcross versus F2 results contrasted by principal component analysis. 2002 , 80, 274-82	52
1201	Colitis-related public T cells are selected in the colonic lamina propria of IL-10-deficient mice. 2002 , 102, 237-48	11
1200	Use of Lactobacillus-GG in paediatric Crohn's disease. 2002 , 34 Suppl 2, S63-5	44
1199	Rapid development of colitis in NSAID-treated IL-10-deficient mice. 2002 , 123, 1527-42	233
1199 1198	Rapid development of colitis in NSAID-treated IL-10-deficient mice. 2002 , 123, 1527-42 Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002 , 122, 94-105	233 150
1198		
1198	Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002 , 122, 94-105	150
1198	Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002 , 122, 94-105 Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. 2002 , 122, 1987-2000 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and	150
1198 1197 1196	Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002 , 122, 94-105 Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. 2002 , 122, 1987-2000 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. 2002 , 123, 689-99 Differential localization of colitogenic Th1 and Th2 cells monospecific to a microflora-associated	150 413 360
1198 1197 1196	Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002, 122, 94-105 Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. 2002, 122, 1987-2000 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. 2002, 123, 689-99 Differential localization of colitogenic Th1 and Th2 cells monospecific to a microflora-associated antigen in mice. 2002, 123, 1949-61 Mucosal and invading bacteria in patients with inflammatory bowel disease compared with	150 413 360 28
1198 1197 1196 1195	Distinct inflammatory mechanisms mediate early versus late colitis in mice. 2002, 122, 94-105 Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. 2002, 122, 1987-2000 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. 2002, 123, 689-99 Differential localization of colitogenic Th1 and Th2 cells monospecific to a microflora-associated antigen in mice. 2002, 123, 1949-61 Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. 2002, 37, 1034-41	150 413 360 28 260

(2003-2002)

1190	Monoassociation of SCID mice with Helicobacter muridarum, but not four other enterics, provokes IBD upon receipt of T cells. 2002 , 122, 1346-54	77
1189	[Probiotics and inflammatory bowel disease]. 2002 , 25, 552-9	1
1188	Microbial factors in inflammatory bowel disease. 2002 , 31, 41-62	105
1187	Immune therapy in inflammatory bowel disease and models of colitis. 2001 , 88, 1558-69	13
1186	Probiotic therapy for pouchitis and its endoscopic findings. 2002 , 14, 47-52	2
1185	Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. 2002 , 17, 849-53	152
1184	Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. 2002 , 8, 71-80	281
1183	Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. 2002 , 8, 347-55	71
1182	Normal Breast Milk Limits the Development of Colitis in IL-10-Deficient Mice. 2002 , 8, 390-8	24
1181	Variable response to probiotics in two models of experimental colitis in rats. 2002 , 8, 399-406	102
1180	Chronic bacterial infections: living with unwanted guests. 2002 , 3, 1026-32	130
1179	Fate of goblet cells in experimental colitis. 2002 , 47, 2286-97	22
1178	Exploring the relationships between intestinal microflora and inflammatory conditions of the human bowel and spine. 2002 , 81, 529-35	10
1177	In situ delivery of cytokines by genetically engineered Lactococcus lactis. 2002 , 82, 323-331	24
1176	Macrophages in the small intestinal muscularis externa of embryos, newborn and adult germ-free mice. 2004 , 35, 377-87	41
1175	Genetics of inflammatory bowel disease: scientific and clinical implications. 2003 , 17, 3-18	50
1174	Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model. 2003, 48, 399-407	2
1173	Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. 2003 , 48, 408-14	88

1172	Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?. 2003 , 18, 1-11		20
1171	Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. 2003 , 5, 115-22		69
1170	Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. 2003 , 134, 127-37		107
1169	Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. 2003 , 9, 87-97		52
1168	Immune networks in animal models of inflammatory bowel disease. 2003 , 9, 246-59		58
1167	Probiotics in inflammatory bowel disease: a critical review. 2003 , 17, 805-20		49
1166	Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. 2003 , 125, 162-77		179
1165	Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. 2003 , 170, 1406-15		383
1164	Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). 2003, 1, 125-36		33
1163	Gut flora in health and disease. 2003 , 361, 512-9		2250
	Gut flora in health and disease. 2003, 361, 512-9 Intestinal flora and mucosal immune responses. 2003, 293, 77-86		2250 49
1162			
1162 1161	Intestinal flora and mucosal immune responses. 2003 , 293, 77-86		49
1162 1161	Intestinal flora and mucosal immune responses. 2003 , 293, 77-86 Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. 2003 , 38, 172-9		49
1162 1161 1160	Intestinal flora and mucosal immune responses. 2003, 293, 77-86 Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. 2003, 38, 172-9 Probiotics and inflammatory bowel disease. 2003, 17, 179-86 Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa		49 32 7
1162 1161 1160 1159	Intestinal flora and mucosal immune responses. 2003, 293, 77-86 Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. 2003, 38, 172-9 Probiotics and inflammatory bowel disease. 2003, 17, 179-86 Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. 2003, 52, 79-83 Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in		49 32 7 183
1162 1161 1160 1159 1158	Intestinal flora and mucosal immune responses. 2003, 293, 77-86 Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. 2003, 38, 172-9 Probiotics and inflammatory bowel disease. 2003, 17, 179-86 Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. 2003, 52, 79-83 Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. 2003, 52, 1721-7 Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic	3.7	49 32 7 183 85

(2004-2003)

1154	Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression. 2003 , 384, 597-607	48
1153	Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. 2003 , 171, 971-8	147
1152	The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. 2003 , 47, 371-8	73
1151	CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. 2003 , 197, 111-9	628
1150	Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. 2003 , 22, 621-31	50
1149	Substance P regulates Th1-type colitis in IL-10 knockout mice. 2003 , 171, 3762-7	57
1148	NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. 2003 , 171, 1484-92	54
1147	The promise of gene therapy in gastrointestinal and liver diseases. 2003 , 52 Suppl 2, ii49-54	20
1146	Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. 2003 , 304, 411-24	78
1145	Fever, night sweats, and a hepatic mass. 2003 , 52, 1727, 1773	1
1144	The role of endogenous bacterial flora: bystander or the necessary prerequisite?. 2003, 15, 615-20	16
1143	Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. 2003 , 19, 358-65	70
1142	Crohn's disease: a defensin deficiency syndrome?. 2003 , 15, 627-34	128
1141	Use of probiotics in the treatment of inflammatory bowel disease. 2003, 36, 111-9	84
1140	Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. 2003 , 21, 105-28	44
1139	The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. 2003 , 133, 21-7	130
1138	Microbial modulation of cytokine networks. 2003 , 223-242	
1137	Probiotics for the maintenance of remission in Crohn's disease. 2004 ,	3

Pathophysiologische Mechanismen der chronisch-entzfildlichen Darmerkrankungen - ein neues Konzept. **2004**, 39, 274-280

1135	Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. 2004 , 64, 962-8		252
1134	Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. 2004 , 286, G613-26		292
1133	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. 2004 , 53, 108-14		651
1132	An abundance of Escherichia coli is harbored by the mucosa-associated bacterial flora of interleukin-2-deficient mice. <i>Infection and Immunity</i> , 2004 , 72, 1983-90	3.7	34
1131	Self inflicted rectal ulcer: hearing is believing. 2004 , 53, 4, 20		
1130	NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. 2004 , 53, 1658-64		602
1129	Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. 2004 , 53, 91-8		60
1128	Antibiotic use and the development of Crohn's disease. 2004 , 53, 246-50		107
1127	Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. 2004 , 53, 1801-5		17
1126	Unravelling the complex genetics of inflammatory bowel disease. 2004 , 89, 598-603		28
1125	Intestinal P glycoprotein acts as a natural defense mechanism against Listeria monocytogenes. <i>Infection and Immunity</i> , 2004 , 72, 3849-54	3.7	25
1124	Dysbiosis in inflammatory bowel disease. 2004 , 53, 1-4		490
1123	Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. 2004 , 53, 685-93		843
1122	Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. 2004 , 11, 372-8		90
1121	Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. 2004 , 136, 30-9		41
1120	Characterization of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell responses in vitro and in vivo. 2004 , 113, 499-508		25
1119	Accelerated alveolar bone loss in mice lacking interleukin-10: late onset. 2004 , 39, 194-8		27

1118	Gene disruption and immunity in experimental colitis. 2004 , 10 Suppl 1, S25-8	6
1117	Interleukin-10 knockout mouse: a model for studying bone metabolism during intestinal inflammation. 2004 , 10, 557-63	24
1116	Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. 2004 , 10, 811-23	51
1115	Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. 2004 , 10, 824-33	71
1114	[Regulatory role of Nod2 in intestinal immunity]. 2004 , 28, 1189-91	
1113	Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer. 2004 , 36, 1481-95	121
1112	High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. 2004 , 49, 1280-6	37
1111	Lipopolysaccharide induces CD25-positive, IL-10-producing lymphocytes without secretion of proinflammatory cytokines in the human colon: low MD-2 mRNA expression in colonic macrophages. 2004 , 24, 42-52	15
1110	Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. 2004 , 93, 97-108	512
1109	Refined histopathologic scoring system improves power to detect colitis QTL in mice. 2004 , 15, 865-71	74
1108	Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. 2004 , 82, 197-205	57
1107	Nitric oxide released by Lactobacillus farciminis improves TNBS-induced colitis in rats. 2004 , 39, 37-45	53
1106	Bacterial probiotic modulation of dendritic cells. <i>Infection and Immunity</i> , 2004 , 72, 3299-309	156
1105	Treatment of inflammatory bowel disease with antibiotics. 2004 , 33, 335-45, x	41
1104	DNA from probiotic bacteria modulates murine and human epithelial and immune function. 2004 , 126, 1358-73	258
1103	Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. 2004 , 126, 1620-33	808
1102	Inflammatory Bowel Disease. 2004 , 649-673	1
1101	The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. 2004 , 15, 61-76	190

1100 Does the microbiota regulate immune responses outside the gut?. 2004 , 12, 562-8	367
Inflammatory Bowel Disease: A Genomic Picture Predicts a Changing Response From the Laboratory Part I. 2004 , 35, 241-243	
Increased incidence of inflammatory bowel disease: the price of the decline of infectious burdent 2004 , 20, 560-4	26
1097 The role of bacterial infection in the pathogenesis of inflammatory bowel disease. 2004 , 43, 534-	9 35
1096 Effect of Intestinal Flora on Phenotype. 2005 , 165-172	
1095 The normal intestinal mucosa: a state of Bontrolled inflammation□ 2003 , 101-120	3
1094 STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. 2005 , 105, 6	89-96 123
Experimental mouse models of inflammatory bowel disease: new insights into pathogenic mechanisms. 2003 , 67-99	
Flaxseed oil and inflammation-associated bone abnormalities in interleukin-10 knockout mice. 20 , 16, 368-74	39
1091 Sporadic colorectal cancerrole of the commensal microbiota. 2005 , 244, 1-7	95
Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. 2005 , 43, 197-204	58
Natural colonization with Helicobacter species and the development of inflammatory bowel disease in interleukin-10-deficient mice. 2005 , 10, 223-30	35
1088 Analysis of the large bowel microbiota of colitic mice using PCR/DGGE. 2005 , 41, 45-51	45
$_{1087}$ Antibacterial and antimycobacterial treatment for inflammatory bowel disease. 2005 , 20, 340-51	7
Species-specific oligonucleotide probes for the detection and identification of Lactobacillus isolated from mouse faeces. 2005 , 99, 51-7	26
The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. 2005 , 115, 375-87	142
1084 The 'microflora hypothesis' of allergic diseases. 2005 , 35, 1511-20	282
Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. 2005 11, 455-63	, 55

(2005-2005)

1082	Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. 2005 , 11, 473-80	200
1081	CD4+CD25+ T cells regulate colonic localization of CD4 T cells reactive to a microbial antigen. 2005 , 11, 541-50	12
1080	Ileal involvement is age dependent in pediatric Crohn's disease. 2005 , 11, 639-44	70
1079	The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. 2005 , 11, 645-52	127
1078	Colitic scid mice fed Lactobacillus spp. show an ameliorated gut histopathology and an altered cytokine profile by local T cells. 2005 , 11, 814-9	30
1077	Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. 2005 , 11, 447-54	59
1076	Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. 2005 , 206, 260-76	404
1075	Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. 2005 , 24, 339-52	89
1074	Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats. 2005 , 205, 43-52	15
1073	Animal models of intestinal inflammation: ineffective communication between coalition members. 2005 , 27, 233-47	22
1072	Cytotoxicity of organic acids produced by anaerobic intestinal bacteria on cultured epithelial cells. 2005 , 40, 600-9	29
1071	De pathogenese van ibd. 2005 , 73, 246-250	
1070	Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. 2005 , 50, 905-13	24
1069	Medical therapy for Crohn⊠ disease. 2003 , 659-680	
1068	Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. 2005, 681-701	11
1067	Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. 2005 , 54, 46-53	94
1066	Crosstalk between NF-kappaB and beta-catenin pathways in bacterial-colonized intestinal epithelial cells. 2005 , 289, G129-37	99
1065	Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. 2005 , 118, 1971-80	74

1064	Viral IL-10-mediated immune regulation in pancreatic islet transplantation. 2005 , 12, 360-8	28
1063	The mucosal inflammatory response. Cytokines and chemokines. 2003 , 147-176	
1062	Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. 2005 , 175, 6900-8	174
1061	Environment as a critical factor for the pathogenesis and outcome of gastrointestinal disease: experimental and human inflammatory bowel disease and helicobacter-induced gastritis. 2005 , 72, 293-307	28
1060	Colon lamina propria dendritic cells induce a proinflammatory cytokine response in lamina propria T cells in the SCID mouse model of colitis. 2005 , 78, 1291-300	23
1059	VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. 2005 , 100, 1539-46	551
1058	Antibiotic use and the risk of flare of inflammatory bowel disease. 2005 , 3, 459-65	38
1057	Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. 2005 , 40, 1334-42	73
1056	Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. <i>Infection and Immunity</i> , 2005 , 73, 912-20	123
1055	Infections and autoimmune diseases. 2005 , 25 Suppl, 74-80	269
1055		269
1054		26937
1054	Role of toll-like receptor: Interactions in intestinal inflammation. 2005, 1285, 3-9	
1054	Role of toll-like receptorBommensal interactions in intestinal inflammation. 2005, 1285, 3-9 Human defensins in Crohn's disease. 2005, 86, 42-54	37
1054 1053 1052	Role of toll-like receptorBommensal interactions in intestinal inflammation. 2005, 1285, 3-9 Human defensins in Crohn's disease. 2005, 86, 42-54 Biologic therapy for inflammatory bowel disease. 2005, 65, 2253-86 Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two	37
1054 1053 1052 1051	Role of toll-like receptorflommensal interactions in intestinal inflammation. 2005, 1285, 3-9 Human defensins in Crohn's disease. 2005, 86, 42-54 Biologic therapy for inflammatory bowel disease. 2005, 65, 2253-86 Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. 2005, 128, 891-906 CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. 2005, 129, 913-27	37 199 340
1054 1053 1052 1051 1050	Role of toll-like receptorflommensal interactions in intestinal inflammation. 2005, 1285, 3-9 Human defensins in Crohn's disease. 2005, 86, 42-54 Biologic therapy for inflammatory bowel disease. 2005, 65, 2253-86 Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. 2005, 128, 891-906 CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. 2005, 129, 913-27	37 199 340 85

(2006-2006)

1046	inflammation. 2006 , 579, 35-54	14
1045	A traditional Japanese medicine mitigates TNBS-induced colitis in rats. 2006 , 41, 1183-9	9
1044	Immune Mechanisms in Inflammatory Bowel Disease. 2006,	6
1043	Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. 2006 , 3, 390-407	1173
1042	Probiotics in Inflammatory Bowel Disease. 2006 , 17, 55-60	
1041	In IBD eight can come before four. 2006 , 131, 667-70	25
1040	Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. 2006 , 131, 1110-21	93
1039	Ecological and evolutionary forces shaping microbial diversity in the human intestine. 2006 , 124, 837-48	2212
1038	TNF alpha production to TLR2 ligands in active IBD patients. 2006 , 119, 156-65	51
1037	IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic mice. 2006 , 34, 85-95	13
1036	Role of toll-like receptors in spontaneous commensal-dependent colitis. 2006 , 25, 319-29	303
1035	Bacteria, inflammation, and colon cancer. 2006 , 12, 6741-6	76
1034	Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. 2006 , 12, 3729-35	124
1033	Inflammatory Bowel Diseases: Ulcerative Colitis and Crohn's Disease. 2006 , 713-728	
1032	Antibiotic therapy for Crohn's disease: a review. 2006 , 20, 651-5	15
1031	Probiotics and prebiotics in chronic inflammatory bowel diseases. 2006 , 12, 5941-50	113
1030	Chemokines in gastrointestinal disorders. 2006 , 7, 47-64	22
1029	The nature of inflammatory bowel disease in patients with coexistent colonic diverticulosis. 2006 , 40, 317-21	58

1028	Cd14, Gbp1, and Pla2g2a: three major candidate genes for experimental IBD identified by combining QTL and microarray analyses. 2006 , 25, 426-34	46
1027	Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. 2006 , 6, 31	89
1026	Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. 2006 , 209, 265-73	45
1025	Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. 2006 , 212, 256-71	387
1024	T cell-mediated oral tolerance is intact in germ-free mice. 2006 , 143, 503-12	28
1023	Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. 2006 , 144, 273-80	48
1022	Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 2006, 23, 1567-74	322
1021	Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. 2006 , 24 Suppl 3, 11-8	128
1020	The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. 2006 , 24, 1105-15	32
1019	Luminal bacterial antigen-specific CD4+ T-cell responses in HLA-B27 transgenic rats with chronic colitis are mediated by both major histocompatibility class II and HLA-B27 molecules. 2006 , 117, 319-28	7
1018	Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells. 2006 , 119, 479-87	19
1017	Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. 2006 , 16, 70-4	35
1016	Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. 2006 , 12 Suppl 1, S3-9	638
1015	Unique dietary-related mouse model of colitis. 2006 , 12, 278-93	36
1014	Use of antibiotics in the treatment of inflammatory bowel disease. 2006 , 12, 651-64	71
1013	Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. 2006 , 12, 853-62	29
1012	Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function. 2006 , 102, 16-24	33
1011	Induction of chronic colitis in IL-10 deficient mice requires IL-4. 2006 , 8, 694-703	19

(2007-2006)

1010	Induction of differential immune reactivity to members of the flora of gnotobiotic mice following colonization with Helicobacter bilis or Brachyspira hyodysenteriae. 2006 , 8, 1602-10	26
1009	Inflammatory bowel disease and Streptococcus bovis. 2006 , 51, 1439-42	10
1008	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. 2006 , 8, 486-98	37
1007	Induction of inflammatory bowel disease accelerates adenoma formation in Min +/- mice. 2006 , 139, 782-8	16
1006	Dietary fatty acids modulate chronic colitis, colitis-associated colon neoplasia and COX-2 expression in IL-10 knockout mice. 2006 , 22, 275-82	48
1005	Probiotics for maintenance of remission in Crohn's disease. 2006 , CD004826	95
1004	Microbial considerations in genetically engineered mouse research. 2006 , 47, 141-55	25
1003	Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. 2006 , 55, 681-8	53
1002	Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. 2006 , 291, G1155-62	23
1001	Probiotics and inflammatory bowel diseases. 2006 , 82, 376-82	54
1000	Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. 2006 , 55, 348-55	291
999	Resistance of C57BL/6 mice to amoebiasis is mediated by nonhemopoietic cells but requires hemopoietic IL-10 production. 2006 , 177, 1208-13	52
998	Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. 2006 , 55, 617-624	157
997	Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. 2006 , 24, 681-704	72
996	Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. **Infection and Immunity, 2006, 74, 4778-92** 3.7	206
995	Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. 2007 , 104, 13780-5	3103
994	Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. 2007 , 23, 2715-28	13
993	Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. 2007 , 56, 934-40	85

992	Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. 2007 , 292, G1630-40	53
991	Maturation of the mucosal immune system underlies colitis susceptibility in interleukin-10-deficient (IL-10-/-) mice. 2007 , 82, 311-9	9
990	Antibiotics protect against septic shock in mice administered beta-glucan and indomethacin. 2007 , 51, 851-9	6
989	Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics. 3.7 Infection and Immunity, 2007 , 75, 3490-7	44
988	Gnotobiotic IL-10-/-;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis. 2007 , 178, 6522-32	102
987	TLR4 signalling in the intestine in health and disease. 2007 , 35, 1473-8	127
986	Inulin and oligofructose in chronic inflammatory bowel disease. 2007, 137, 2572S-2575S	63
985	Probiotic effects on inflammatory bowel disease. 2007 , 137, 819S-24S	118
984	Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus. 2007 , 31, 598-606	130
983	Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. 2007 , 41 Suppl 1, S37-43	42
982	Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. 2007, 361, 953-9	11
981	The role of microbes in Crohn's disease. 2007 , 44, 256-62	154
980	The immune response in inflammatory bowel disease. 2007 , 102, 2058-69	163
979	Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. 2007 , 56, 1522-8	317
978	[Probiotics and prebiotics in inflammatory bowel disease]. 2007, 30, 419-25	1
977	Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. 2007 , 133, 1869-81	492
976	Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. 2007 , 66, 307-15	141
975	The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules. 2007 , 2, e596	46

974	Role of bacteria in the etiopathogenesis of inflammatory bowel disease. 2007 , 13, 5571-6	57
973	Gastrointestinal Regenerative Engineering. 798-818	
972	Therapeutic effects of roxithromycin in interleukin-10-deficient colitis. 2007 , 13, 547-56	11
971	The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice. 2007 , 13, 490-500	12
970	Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. 2007 , 13, 955-62	81
969	Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. 2007 , 13, 1153-64	79
968	Adherent-invasive Escherichia coli in inflammatory bowel disease. 2007, 13, 1277-83	172
967	Dual-association of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. 2007 , 13, 1457-66	105
966	Methotrexate-induced mucositis in mucin 2-deficient mice. 2007 , 210, 144-52	24
965	Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. 2007 , 8, 4	129
964	Alveolar bone loss in T helper 1/T helper 2 cytokine-deficient mice. 2007 , 42, 97-103	36
963	Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. 2007 , 8, 931-41	453
962	Unravelling the pathogenesis of inflammatory bowel disease. 2007, 448, 427-34	3005
961	Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. 2008 , 89, 45-54	20
960	Review article: Probiotics in gastrointestinal and liver diseases. 2007 , 26 Suppl 2, 133-48	56
959	T-cell activation in the intestinal mucosa. 2007 , 215, 189-201	49
958	Secretory immunoglobulin A (sIgA) deficiency in serum of patients with GALTectomy (appendectomy and tonsillectomy). 2007 , 123, 289-97	33
957	Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. 2007 , 114, 267-74	95

956	Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. 2007 , 115, 1-11	119
955	Helminths as governors of immune-mediated inflammation. 2007 , 37, 457-64	151
954	Enteral administration of hematopoietic growth factors in the neonatal intensive care unit. 2002 , 91, 43-53	8
953	Nutrigenomics applied to an animal model of Inflammatory Bowel Diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and arachidonic acid-enriched diets. 2007 , 622, 103-16	49
952	A cytokine-mediated link between innate immunity, inflammation, and cancer. 2007, 117, 1175-83	1363
951	Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. 2007 , 12, 598-604	30
950	Effects of monocolonization with Escherichia coli strains O6K13 and Nissle 1917 on the development of experimentally induced acute and chronic intestinal inflammation in germ-free immunocompetent and immunodeficient mice. 2007 , 52, 618-26	15
949	Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis. 2007, 56, 439-46	11
948	High proportions of proinflammatory bacteria on the colonic mucosa in a young patient with ulcerative colitis as revealed by cloning and sequencing of 16S rRNA genes. 2007 , 52, 620-7	38
947	Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. 2008 , 53, 2495-506	32
946	Mechanisms regulating the development and function of natural regulatory T cells. 2008, 56, 85-102	12
945	Abnormalities in the handling of intracellular bacteria in Crohn's disease: a link between infectious etiology and host genetic susceptibility. 2008 , 56, 237-44	23
944	Alternative drug delivery approaches for the therapy of inflammatory bowel disease. 2008, 97, 2878-91	58
943	Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. 2008 , 14, 471-9	14
942	Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. 2008 , 14, 1012-8	174
941	Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease. 2008, 14, 1641-51	30
940	Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. 2008 , 122, 832-8	54
939	Mucosal macrophages and the regulation of immune responses in the intestine. 2008 , 119, 22-31	86

938	Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. 2008, 226, 219-33	225
937	Molecular-phylogenetic characterization of microbial communities imbalances in the small intestine of dogs with inflammatory bowel disease. 2008 , 66, 579-89	148
936	Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice. 2008 , 88, 634-42	27
935	A microbial symbiosis factor prevents intestinal inflammatory disease. 2008 , 453, 620-5	1698
934	Role of Toll-like receptors in gastrointestinal malignancies. 2008, 27, 234-43	148
933	Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. 2008 , 151, 34-41	134
932	Strategies for use of IL-10 or its antagonists in human disease. 2008 , 223, 114-31	318
931	Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. 2008 , 28, 724-33	120
930	Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. 2008, 65, 453-67	100
929	Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and non-ulcerative colitis subjects. 2008 , 105, 706-14	102
928	[Helminths and inflammatory bowel diseases]. 2008, 32, 1064-74	2
928	[Helminths and inflammatory bowel diseases]. 2008, 32, 1064-74 Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. 2008, 127, 270-9	2
	Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and	
927	Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. 2008, 127, 270-9 Imbalance in intestinal microflora constitution could be involved in the pathogenesis of	4
927 926	Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. 2008, 127, 270-9 Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. 2008, 298, 463-72 Contextual regulation of inflammation: a duet by transforming growth factor-beta and	229
927 926 925	Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. 2008, 127, 270-9 Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. 2008, 298, 463-72 Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. 2008, 28, 468-76	4 229 366
927 926 925 924	Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. 2008, 127, 270-9 Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. 2008, 298, 463-72 Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. 2008, 28, 468-76 Immunogenicity and pathogenicity of Helicobacter infections of veterinary animals. 2008, 122, 191-203	4 229 366 18

920	Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. 2008 , 68, 10280-9	172
919	Gastrointestinal and Liver Microcirculations: Roles in Inflammation and Immunity. 2008, 684-711	
918	What is the role of the metabolic activity of the gut microbiota in inflammatory bowel disease? Probing for answers with stable isotopes. 2008 , 46, 486-95	17
917	Colonization with Heligmosomoides polygyrus suppresses mucosal IL-17 production. 2008 , 181, 2414-9	92
916	Impaired Bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice. 2008 , 283, 14182-9	30
915	Polyclonal MHC Ib-restricted CD8+ T cells undergo homeostatic expansion in the absence of conventional MHC-restricted T cells. 2008 , 180, 2805-14	6
914	Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. 2008 , 181, 1143-52	124
913	Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. 2008 , 295, G1079-91	56
912	Anti-inflammatory implications of the microbial transformation of dietary phenolic compounds. 2008 , 60, 636-42	54
911	Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. 2008 , 205, 2191-8	230
911	Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. 2008 , 205, 2191-8 An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008 , 5, e41	230 96
910	An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008 , 5, e41 Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in	96
910	An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008, 5, e41 Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in children. 2008, 64, 677-81	96
910 909 908	An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008, 5, e41 Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in children. 2008, 64, 677-81 The role of IL-10 in preventing food-induced anaphylaxis. 2008, 8, 1309-17 Massive but selective cytokine dysregulation in the colon of IL-10-/- mice revealed by multiplex	96 3 8
910 909 908 907	An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008, 5, e41 Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in children. 2008, 64, 677-81 The role of IL-10 in preventing food-induced anaphylaxis. 2008, 8, 1309-17 Massive but selective cytokine dysregulation in the colon of IL-10-/- mice revealed by multiplex analysis. 2008, 20, 141-54	96 3 8
910909908907906	An antibiotic-responsive mouse model of fulminant ulcerative colitis. 2008, 5, e41 Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in children. 2008, 64, 677-81 The role of IL-10 in preventing food-induced anaphylaxis. 2008, 8, 1309-17 Massive but selective cytokine dysregulation in the colon of IL-10-/- mice revealed by multiplex analysis. 2008, 20, 141-54 The pathogenic role of intestinal flora in IBD and colon cancer. 2008, 9, 395-403	96 3 8 17 38

902	Application of prodrugs to inflammatory diseases of the gut. 2008 , 13, 452-74	28
901	[Association of Toll-like receptor gene with Crohn's disease in Koreans]. 2009 , 54, 377-83	3
900	Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. 2009 , 15, 5287-94	107
899	Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. 2009 , 4, e4561	22
898	Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. 2009 , 4, e6026	321
897	Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. 2009 , 104, 404-10	125
896	Charles River altered Schaedler flora (CRASF) remained stable for four years in a mouse colony housed in individually ventilated cages. 2009 , 43, 362-70	42
895	Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. 2009 , 58, 535-545	99
894	Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. 2009, 183, 2312-20	227
893	Intestinal immune regulation as a potential diet-modifiable feature of gut inflammation and autoimmunity. 2009 , 28, 414-45	27
892	Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice. <i>Infection and Immunity</i> , 2009 , 77, 2508-16	56
891	Helminthic therapy: using worms to treat immune-mediated disease. 2009 , 666, 157-66	48
890	Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. 2009 , 36, S84-91	45
889	Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. 2009 , 15, 2066-73	33
888	Relevance of nutritional antioxidants in metabolic syndrome, ageing and cancer: potential for therapeutic targeting. 2009 , 9, 400-14	56
887	Role of intestinal mucins in innate host defense mechanisms against pathogens. 2009 , 1, 123-35	209
886	The Role of Microbiota in Inflammatory Bowel Disease. 2009 , 67, 27-38	2
885	Genetics of ulcerative colitis: the come-back of interleukin 10. 2009 , 58, 1173-6	15

884	Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 2009 , 237, 69-82	52
883	Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC). 2009 , 9, 202	67
882	Mechanisms of action of probiotics: recent advances. 2009 , 15, 300-10	357
881	Prebiotics in chronic intestinal inflammation. 2009 , 15, 454-62	115
880	Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. 2009 , 15, 508-14	35
879	Gene expression patterns in experimental colitis in IL-10-deficient mice. 2009 , 15, 890-9	45
878	Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. 2009 , 15, 872-82	270
877	Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. 2009 , 15, 1022-31	43
876	Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. 2009 , 15, 1174-82	34
875	Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. 2009 , 39, 2021-6	38
874	Infection with murine gammaherpesvirus 68 exacerbates inflammatory bowel disease in IL-10-deficient mice. 2009 , 58, 881-9	17
873	A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. 2009 , 128, e170-80	77
872	Anti-inflammatory effects of the genus Bifidobacterium on macrophages by modification of phospho-I kappaB and SOCS gene expression. 2009 , 90, 131-40	44
871	Faecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. 2009 , 29, 75-82	51
870	The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. 2009 , 156, 172-82	46
869	16S rRNA gene sequence-based analysis of clostridia related to conversion of germfree mice to the normal state. 2009 , 107, 2088-97	24
868	Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. 2009 , 10, 356-64	67
867	A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. 2009 , 10, 471-9	143

(2009-2009)

866	The gut microbiota shapes intestinal immune responses during health and disease. 2009 , 9, 313-23	3119
865	Intestinal mucosal barrier function in health and disease. 2009 , 9, 799-809	2090
864	Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. 2009 , 11, 1562-71	42
863	Actobiotics as a novel method for cytokine delivery. 2009 , 1182, 135-45	28
862	Endogenous antigen presenting cell-derived IL-10 inhibits T lymphocyte responses to commensal enteric bacteria. 2009 , 123, 77-87	12
861	Loss of Toll-like receptor 2 and 4 leads to differential induction of endoplasmic reticulum stress and proapoptotic responses in the intestinal epithelium under conditions of chronic inflammation. 2009 , 8, 4406-17	22
860	Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. 2009 , 9, 447-53	381
859	Intestinal microflora and metabolic diseases. 2009 , 35, 262-72	63
858	Mouse models of colon cancer. 2009 , 136, 780-98	183
857	Oxazolone-induced enterocolitis in zebrafish depends on the composition of the intestinal microbiota. 2009 , 137, 1757-67.e1	94
856	Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. 2009, 8, 2045-57	56
855	Microbial-host interactions in inflammatory bowel diseases and experimental colitis. 2009 , 64, 121-32; discussion 132-7, 251-7	22
854	The role of macrophages in inflammatory bowel diseases. 2009 , 11, e14	59
853	Pathogen-Derived Immunomodulatory Molecules. 2009,	
852	Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. 2009 , 47, 453-5	107
851	The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. 2009 , 7, 1202-9, 1209.e1	350
850	The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. 2009 , 25, 496-502	76
849	El papel de la microbiota en la enfermedad inflamatoria intestinal. 2009 , 67, 27-38	O

848 3 Wechselwirkung zwischen Darmflora und intestinalem Immunsystem. 2009,

847	Rôle du microbiote dans les maladies inflammatoires de l’intestin. 2009 , 67, 27-38	
846	Detection of Helicobacteraceae in intestinal biopsies of children with Crohn's disease. 2010 , 15, 549-57	33
845	Multistep mechanism of probiotic bacterium, the effect on innate immune system. 2010 , 54, 277-84	34
844	The role of infection in the aetiology of inflammatory bowel disease. 2010 , 45, 266-76	93
843	Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. 2010 , 705, 40-59	84
842	Molecular analysis of the bacterial microbiota in duodenal biopsies from dogs with idiopathic inflammatory bowel disease. 2010 , 142, 394-400	114
841	Toll-like receptors in inflammatory bowel diseases: a decade later. 2010 , 16, 1583-97	244
840	Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. 2010 , 11, 39	46
839	Host-bacteria interactions in the intestine: homeostasis to chronic inflammation. 2010 , 2, 80-97	27
838	Role of SIRP#n regulation of mucosal immunity in the intestine. 2010 , 15, 1189-200	8
837	An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens. 2010 , 161, 187-96	17
836	The regulation of IL-10 production by immune cells. 2010 , 10, 170-81	1886
835	The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. 2010 , 8, 564-77	266
834	Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. 2010 , 25 Suppl 1, S62-6	17
833	Genetic Monitoring of Laboratory Rodents. 2010 , 461-469	1
832	Community dynamics in the mouse gut microbiota: a possible role for IRF9-regulated genes in community homeostasis. 2010 , 5, e10335	29
831	Chronic effects of a Salmonella type III secretion effector protein AvrA in vivo. 2010 , 5, e10505	59

(2010-2010)

830	Prebiotics and Probiotics in Experimental Models of Rodent Colitis: Lessons in Treatment or Prevention of Inflammatory Bowel Diseases. 2010 , 589-610	1
829	Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. 2010 , 15, 25-34	169
828	Diversity of caecal bacteria is altered in interleukin-10 gene-deficient mice before and after colitis onset and when fed polyunsaturated fatty acids. 2010 , 156, 3306-3316	12
827	Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. 2010 , 207, 1321-32	174
826	Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. <i>Gut Microbes</i> , 2010 , 1, 138-47	272
825	Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. 2010 , 2010, 671258	17
824	TGF-beta-activated kinase 1 signaling maintains intestinal integrity by preventing accumulation of reactive oxygen species in the intestinal epithelium. 2010 , 185, 4729-37	44
823	Effects of fructo-oligosaccharide on DSS-induced colitis differ in mice fed nonpurified and purified diets. 2010 , 140, 2121-7	27
822	Links between innate immunity and normal tissue radiobiology. 2010 , 173, 406-17	91
821	Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. 2010 , 105, 1820-9	92
820	Prebiotic effects: metabolic and health benefits. 2010 , 104 Suppl 2, S1-63	1440
819	Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 2010 , 184, 4069-73	64
818	How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation. 2010 , 2010, 574568	21
817	Microbial regulation of SAA3 expression in mouse colon and adipose tissue. <i>Gut Microbes</i> , 2010 , 1, 55-578.8	13
816	Lactobacillus plantarum ameliorates colonic epithelial barrier dysfunction by modulating the apical junctional complex and PepT1 in IL-10 knockout mice. 2010 , 299, G1287-97	46
815	The probiotic paradox: live and dead cells are biological response modifiers. 2010 , 23, 37-46	308
814	Role of the gut microbiota in defining human health. 2010 , 8, 435-54	265
813	Intestinal bacteria and the regulation of immune cell homeostasis. 2010 , 28, 623-67	403

812	Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110 2010 , 139, 1642-53, 1653.e1-6	64
811	Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species. 2010 , 5, 759-74	75
810	Inflammatory bowel disease. 2010 , 28, 573-621	1390
809	Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial. 2010 , 24, 269-77	60
808	The Family of IL-10-secreting CD4+ T cells. 2010 , 105, 99-130	121
807	Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. 2010 , 177, 686-97	178
806	TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. 2010 , 107, 4293-8	28
805	The role of IL-10 in regulating immunity to persistent viral infections. 2011 , 350, 39-65	100
804	Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. 2010 , 9, 1965-75	58
803	Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. 2011 , 60, 26-33	85
802	Depletion of gut commensal bacteria attenuates intestinal ischemia/reperfusion injury. 2011 , 301, G1020-30	62
801	Importance and regulation of the colonic mucus barrier in a mouse model of colitis. 2011 , 300, G327-33	226
800	Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. 2011 , 106, 661-73	390
799	Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli. 2011 , 141, 1842-51.e1-10	66
798	Unlocking the gates to inflammatory bowel disease: the role of Enterococcus faecalis gelatinase. 2011 , 141, 795-8	3
797	Lipoteichoic acid-deficient Lactobacillus acidophilus regulates downstream signals. 2011 , 3, 337-47	25
796	KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-[production. 2011 , 140, 265-74	21
795	Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. 2011 , 141, 653-62, 662.e1-4	66

794	The role of human defensins in gastrointestinal diseases. 2011 , 7, 779-87		8
793	The role of IL-10 in immune regulation during M. tuberculosis infection. <i>Mucosal Immunology</i> , 2011 , 4, 261-70	9.2	307
792	Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. 2011 , 9, 390-403		334
791	Transcription of the Tollip gene is elevated in intestinal epithelial cells through impaired O-GlcNAcylation-dependent nuclear translocation of the negative regulator Elf-1. 2011 , 412, 704-9		14
79°	Inflammation enhances resection-induced intestinal adaptive growth in IL-10 null mice. 2011 , 168, 62-9		11
789	Role of gut microbiota in graft-versus-host disease. 2011 , 52, 1844-56		42
788	The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. 2011 , 140, 1720-28		324
787	Adaptive immunity in the host-microbiota dialog. <i>Mucosal Immunology</i> , 2011 , 4, 15-21	9.2	74
786	Animal Models of Colitis: Lessons Learned, and Their Relevance to the Clinic. 2011,		7
785	Mouse models of colorectal cancer. 2011 , 30, 450-62		17
7 ⁸ 4	Effect of Lactobacillus plantarum LP-Onlly on gut flora and colitis in interleukin-10 knockout mice. 2011 , 26, 405-11		27
783	Prebiotics: germinated barley foodstuff for the prevention of colitis-associated colon cancer?. 2011 , 26, 1219-20		6
782	Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. 2011 , 34, 497-508		78
781	Bacteria and spontaneous experimental colitis: immunological changes. 2011 , 41, 1047-53		6
780	Lactobacillus reuteri promotes Helicobacter hepaticus-associated typhlocolitis in gnotobiotic B6.129P2-IL-10(tm1Cgn) (IL-10(-/-)) mice. 2011 , 133, 165-78		28
779	Dendritic cell control of tolerogenic responses. 2011 , 241, 206-27		252
778	The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. 2011 , 8, 110-20		455
777	NF- B in the regulation of epithelial homeostasis and inflammation. 2011 , 21, 146-58		319

776	Regulation and functions of the IL-10 family of cytokines in inflammation and disease. 2011 , 29, 71-109	1132
775	CITED2 is activated in ulcerative colitis and induces p53-dependent apoptosis in response to butyric acid. 2011 , 46, 339-49	12
774	Ectopic expression of blood type antigens in inflamed mucosa with higher incidence of FUT2 secretor status in colonic Crohn's disease. 2011 , 46, 1056-63	25
773	Quantitative trait loci in a bacterially induced model of inflammatory bowel disease. 2011 , 22, 544-55	9
772	Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis. 2011 , 60, 1049-59	5
771	Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. 2011 , 51, 170-82	181
770	Update on the management of Crohn's disease. 2011 , 13, 465-74	22
769	Impact of a probiotic Enterococcus faecalis in a gnotobiotic mouse model of experimental colitis. 2011 , 55, 703-13	14
768	Metabolomic analysis reveals differences in urinary excretion of kiwifruit-derived metabolites in a mouse model of inflammatory bowel disease. 2011 , 55, 1900-4	9
767	Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. 2011 , 41, 182-94	60
766	The struggle within: microbial influences on colorectal cancer. 2011 , 17, 396-409	91
765	Genetics of ulcerative colitis. 2011, 17, 831-48	106
764	Importance of disrupted intestinal barrier in inflammatory bowel diseases. 2011 , 17, 362-81	340
763	Using metabolomic analysis to understand inflammatory bowel diseases. 2011 , 17, 1021-9	47
762	Enteroantigen-presenting B cells efficiently stimulate CD4(+) T cells in vitro. 2011 , 17, 308-18	7
761	Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. 2011 , 17, 917-26	143
760	Aberrant response to commensal Bacteroides thetaiotaomicron in Crohn's disease: an ex vivo human organ culture study. 2011 , 17, 1201-8	18
759	Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10. 2011 , 17, 2038-46	39

(2011-2011)

75 ⁸	IL-27 induces the differentiation of Tr1-like cells from human naive CD4+ T cells via the phosphorylation of STAT1 and STAT3. 2011 , 136, 21-8		64
757	NHE3 modulates the severity of colitis in IL-10-deficient mice. 2011 , 300, G998-G1009		23
756	Extracellular matrix-associated cytokines regulate CD4+ effector T-cell responses in the human intestinal mucosa. <i>Mucosal Immunology</i> , 2011 , 4, 420-7	9.2	11
755	Inflammatory Bowel Disease. 2011,		2
754	Intestinal dysbiosis in inflammatory bowel disease. <i>Gut Microbes</i> , 2011 , 2, 211-6	8.8	85
753	Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. 2011 , 186, 3642-52		128
75 ²	SR-PSOX/CXCL16 plays a critical role in the progression of colonic inflammation. 2011 , 60, 1494-505		30
751	Intestinal microbiota in inflammatory bowel disease: friend of foe?. 2011 , 17, 557-66		205
75°	NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity. 2011 , 186, 4649-55		75
749	Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. <i>Infection and Immunity</i> , 2011 , 79, 2597-607	3.7	93
748	The role of microbes in developmental immunologic programming. 2011 , 69, 465-72		131
747	Beneficial Microorganisms in Multicellular Life Forms. 2011 ,		11
746	Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy. 2011 , 186, 3726-34		11
745	Cytokines, inflammation and colon cancer. 2011 , 11, 451-64		197
744	Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-Esignaling pathways regulates the innate inflammatory response. 2011 , 186, 5217-26		86
743	Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. 2011 , 108 Suppl 1, 4623-30		186
742	The role of glycogen synthase kinase 3 in regulating IFN-Emediated IL-10 production. 2011 , 186, 675-84		60
74 ¹	Dietary Eglucan regulates the levels of inflammatory factors, inflammatory cytokines, and immunoglobulins in interleukin-10 knockout mice. 2011 , 14, 468-74		15

740	The Yin and Yang of host-commensal mutualism. <i>Gut Microbes</i> , 2011 , 2, 347-52	8.8	7
739	Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. <i>Mucosal Immunology</i> , 2011 , 4, 127-32	9.2	60
738	Colitis development during the suckling-weaning transition in mucin Muc2-deficient mice. 2011 , 301, G667-78		24
737	Prenatal programming of the innate immune response following in utero exposure to inflammation: a sexually dimorphic process?. 2011 , 7, 579-92		24
736	New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. 2012 , 2012, 560817		50
735	Reduced lesions in chickens with Clostridium perfringens-induced necrotic enteritis by Lactobacillus fermentum 1.20291. 2012 , 91, 3065-71		55
734	Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. <i>Frontiers in Immunology</i> , 2012 , 3, 107	8.4	225
733	Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. <i>Infection and Immunity</i> , 2012 , 80, 388-97	3.7	30
73 ²	Comparative study on experimental autoimmune pancreatitis and its extrapancreatic involvement in mice. 2012 , 41, 1255-62		17
731	The role of gut microbiota in immune homeostasis and autoimmunity. <i>Gut Microbes</i> , 2012 , 3, 4-14	8.8	517
730	Effects of kiwifruit extracts on colonic gene and protein expression levels in IL-10 gene-deficient mice. 2012 , 108, 113-29		17
729	Interleukin-1[IL-1] promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis. 2012 , 61, 373-84		59
728	Epithelial cell-intrinsic Notch signaling plays an essential role in the maintenance of gut immune homeostasis. 2012 , 188, 2427-36		51
727	The intestinal microbiome of the pig. 2012 , 13, 100-9		188
726	MIP-3\pression in macrophages is NOD dependent. 2012 , 85, 192-201		3
725	TNF-Emediates macrophage-induced bystander effects through Netrin-1. 2012 , 72, 5219-29		26
724	Immune modulation by regulatory T cells in Helicobacter pylori-associated diseases. 2012 , 12, 71-85		31
723	Gastrointestinal infection as a trigger for inflammatory bowel disease. 2012 , 28, 24-9		51

722	Environmental factors and their impact on the intestinal microbiota: a role for human disease?. 2012 , 30 Suppl 3, 20-7	7
721	Importance of Commensal and Probiotic Bacteria in Human Health. 2012 , 8, 248-253	4
720	What can gut bacteria tell us about colorectal cancer?. 2012 , 1, 265-268	1
719	Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. 2012 , 3, 27-43	149
718	TLR9 is important for protection against intestinal damage and for intestinal repair. <i>Scientific Reports</i> , 2012 , 2, 574	52
717	Recycling endosome-dependent and -independent mechanisms for IL-10 secretion in LPS-activated macrophages. 2012 , 92, 1227-39	28
716	Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. 2012 , 12, 139-52	325
715	Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. 2012 , 178, 147-54	6
714	Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. 2012 , 148, 126-32	30
713	Enteric pathogens through life stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012 , 2, 114 5.9	44
713 712	Enteric pathogens through life stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012 , 2, 114 5.9 Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012 , 13, 916-24	128
	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways.	
712	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012 , 13, 916-24 Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and	128
712 711	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012 , 13, 916-24 Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012 , 87, 701-30	128 94
712 711 710	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012, 13, 916-24 Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012, 87, 701-30 MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. 2012, 3, 1120 Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics.	128 94 105
712 711 710 709	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012, 13, 916-24 Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012, 87, 701-30 MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. 2012, 3, 1120 Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. 2012, 590, 1035-44	128 94 105
712 711 710 709 708	Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. 2012, 13, 916-24 Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012, 87, 701-30 MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. 2012, 3, 1120 Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. 2012, 590, 1035-44 Role of commensal gut bacteria in inflammatory bowel diseases. <i>Gut Microbes</i> , 2012, 3, 544-55 8.8	128 94 105 171 113

704	The gut microflora and its variety of roles in health and disease. 2013 , 358, 273-89	39
703	Mouse background strain profoundly influences Paneth cell function and intestinal microbial composition. 2012 , 7, e32403	58
702	Mucin Muc2 deficiency and weaning influences the expression of the innate defense genes Reg3 Reg3 and angiogenin-4. 2012 , 7, e38798	56
701	Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. 2012 , 32, 23-63	607
700	Engineering High-Affinity T Cell Receptor/ Cytokine Fusions for Therapeutic Targeting. 2012,	
699	The Role of the Microbiota in Gastrointestinal Health and Disease. 2012 ,	1
698	Pathogenesis of Inflammatory Bowel Diseases. 2012,	1
697	Innate and adaptive immunity in host-microbiota mutualism. 2012 , 4, 685-98	11
696	IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis. 2012 , 189, 1792-9	60
695	Anti-inflammatory properties of dairy lactobacilli. 2012 , 18, 657-66	46
694	Role of the microbiota in inflammatory bowel diseases. 2012 , 18, 968-84	198
693	Gene expression profiling identifies mechanisms of protection to recurrent trinitrobenzene sulfonic acid colitis mediated by probiotics. 2012 , 18, 1424-33	22
692	Microbial and histopathologic considerations in the use of mouse models of inflammatory bowel diseases. 2012 , 18, 1558-65	10
691	A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. 2012 , 10, 575-82	475
690	Microbial translocation across the GI tract. 2012 , 30, 149-73	294
689	Novel players in inflammatory bowel disease pathogenesis. 2012 , 14, 146-52	20
688	Probiotics for the treatment of inflammatory bowel disease. 2012 , 14, 324-33	80
687	Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis. 2012 , 50, 218-25	35

(2013-2012)

686	diseases. 2012 , 165, 820-8	10
685	Inflamed gut mucosa: downstream of interleukin-10. 2012 , 42, 95-109	76
684	Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. 2012 , 24, 31-9	152
683	Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. 2012 , 245, 164-76	152
682	Inflammatory bowel disease. 2012 , 18, 1-15	35
681	Time to include the gut microbiota in the hygienic standardisation of laboratory rodents. 2012 , 35, 81-92	56
680	Perspectives on tight junction research. 2012 , 1257, 1-19	37
679	Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. 2012 , 27, 1205-12	44
678	Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. 2012 , 62, 368-80	38
677	Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. 2012 , 18, 372-90	79
676	Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. 2013 , 19, 141-50	53
675	Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. 2013 , 140, 87-97	90
674	Inflammatory Bowel Disease. 2013 , 1-38	
673	Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. 2013 , 48, 315-21	98
672	The effects of intestinal microbial community structure on disease manifestation in IL-10-/- mice infected with Helicobacter hepaticus. 2013 , 1, 15	24
671	Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. 2013 , 69, 42-51	229
670	Regulatory T cells and immune tolerance in the intestine. 2013 , 5,	74
669	Review of the association between meat consumption and risk of colorectal cancer. 2013 , 33, 983-94	115

668	Deciphering bacterial universal language by detecting the quorum sensing signal, autoinducer-2, with a whole-cell sensing system. 2013 , 85, 9604-9	26
667	Screening metatranscriptomes for toxin genes as functional drivers of human colorectal cancer. 2013 , 27, 85-99	28
666	Microbial fingerprinting detects intestinal microbiota dysbiosis in Zebrafish models with chemically-induced enterocolitis. 2013 , 13, 289	38
665	Experimental approaches for defining functional roles of microbes in the human gut. 2013 , 67, 459-75	31
664	Evidence for Contributions of Gut Microbiota to Colorectal Carcinogenesis. 2013, 2, 10-18	7
663	Immune aspects of the pathogenesis of inflammatory bowel disease. 2013 , 137, 283-97	64
662	Mon cerveau et mon intestin communiquent, parfois mal !. 2013 , 4, 240-257	0
661	Mucosal immunity in liver autoimmunity: a comprehensive review. 2013 , 46, 97-111	87
660	Interleukin-10 prevents epithelial cell apoptosis by regulating IFN and TNF expression in rhesus macaque colon explants. 2013 , 64, 30-4	9
659	Effect of barrier microbes on organ-based inflammation. 2013 , 131, 1465-78	45
658	Intestinal Microbes, Diet, and Colorectal Cancer. 2013 , 9, 95-105	10
657	The dynamics of gut-associated microbial communities during inflammation. 2013 , 14, 319-27	213
656	Role of the gut microbiota in the development and function of lymphoid cells. 2013, 190, 1389-95	98
655	Role of the gut microbiota in immunity and inflammatory disease. 2013 , 13, 321-35	1263
654	RNA decay tolerizes: MCPIP1 (Zc3h12a) keeps inflammation in check by cleaving 3' UTRs. 2013, 91, 331-2	2
653	Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. 2013 , 150, 30-40	71
652	Preface. Between Pathogenicity and Commensalism. 2013 , 358, v-vii	4
651	Mucus and the goblet cell. 2013 , 31, 305-9	72

650	Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. 2013 , 73, 5905-13		200
649	Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. 2013 , 73, 7199-210		73
648	Reduced colonic microbial diversity is associated with colitis in NHE3-deficient mice. 2013, 305, G667-77		57
647	Regulatory T Cells Control Immune Responses through Their Non-Redundant Tissue Specific 8	4	27
646	Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. 2013 , 304, G597-604		31
645	Customizing laboratory mice by modifying gut microbiota and host immunity in an early "window of opportunity". <i>Gut Microbes</i> , 2013 , 4, 241-5	8	27
644	White button mushrooms increase microbial diversity and accelerate the resolution of Citrobacter rodentium infection in mice. 2013 , 143, 526-32		21
643	Biology and Regulation of Blood-Tissue Barriers. 2013 ,		2
642	1,4-Dihydroxy-2-naphthoic acid from Propionibacterium freudenreichii reduces inflammation in interleukin-10-deficient mice with colitis by suppressing macrophage-derived proinflammatory cytokines. 2013 , 94, 473-80		16
641	Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. 2013 , 33, 2275-84		32
640	Interactions Between Diet and Gut Microbes in Inflammatory Bowel Disease. 2013, 39, 1-5		
639	Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders. 2013 , 72, 288-98		31
638	Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. 2013, 2013, 435268		116
637	Regulation of adaptive immunity; the role of interleukin-10. <i>Frontiers in Immunology</i> , 2013 , 4, 129	4	192
636	Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. <i>Gut Microbes</i> , 2013 , 4, 316-24	8	91
635	Investigational cytokine-targeted therapies for ulcerative colitis. 2013 , 22, 1123-32		2
634	Inflammation-induced acid tolerance genes gadAB in luminal commensal Escherichia coli attenuate experimental colitis. <i>Infection and Immunity</i> , 2013 , 81, 3662-71	7	20
633	Higher fecal bile acid hydrophobicity is associated with exacerbation of dextran sodium sulfate colitis in mice. 2013 , 143, 1691-7		19

632	Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. 2013 , 143, 1679-86	199
631	Medical management of Crohn⊠ disease. 2013 , 104-122	
630	Environmental factors and inflammatory bowel disease: elusive or nonexistent?. 2013, 19, 548-9	4
629	Colitis-induced bone loss is gender dependent and associated with increased inflammation. 2013 , 1586-97	43
628	Bacteriophages in gut samples from pediatric Crohn's disease patients: metagenomic analysis using 454 pyrosequencing. 2013 , 19, 1598-608	95
627	Upregulation of superoxide dismutase activity in the intestinal tract mucosa of germ-free mice. 2013 , 75, 49-54	5
626	Enterohepatic Helicobacter other than Helicobacter pylori. 2013 , 105, 477-84	19
625	Autophagy in the Gastrointestinal Tract. 2013 , 57-88	
624	CD137 facilitates the resolution of acute DSS-induced colonic inflammation in mice. 2013 , 8, e73277	11
623	Impact of the gut microbiota on rodent models of human disease. 2014 , 20, 17727-36	55
622	Dominant effects of the diet on the microbiome and the local and systemic immune response in mice. 2014 , 9, e86366	32
621	The gut microbiota in mouse models of inflammatory bowel disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014 , 4, 28	97
620	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. 2014 , 20, 11505-24	123
619	Intestinal barrier in inflammatory bowel disease. 2014 , 20, 1165-79	195
618	Current status and prospects of intestinal microbiome studies. 2014 , 12, 178-83	13
617	Manipulation of Microbiome, a Promising Therapy for Inflammatory Bowel Diseases. 2014 , 05,	2
616	Transcriptional regulation of IL-10 and its cell-specific role in vivo. 2014 , 34, 315-45	26
615	LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production. 2014 , 289, 22980-22990	40

614	Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice. 2014 , 177, 94-101		27
613	Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. 2014 , 3, e105		105
612	A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection. 2014 , 10, e1004264		77
611	Heat-killed VSL#3 ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in rats. 2013 , 15, 15-28		19
610	NOD-like receptors in intestinal homeostasis and epithelial tissue repair. 2014 , 15, 9594-627		55
609	Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. 2014 , 63, 281-91		535
608	Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. 2014 , 7, ra43		37
607	Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. <i>Frontiers in Immunology</i> , 2014 , 5, 125	8.4	83
606	The intestinal microbiota in inflammatory bowel diseases. 2014 , 79, 29-39		28
605	Enteroantigen (eAg)-binding B lymphocytes in the mouse - phenotype, distribution, function and eAg-specific antibody secretion. 2014 , 122, 616-27		3
604	Role of the intestinal microbiota and fecal transplantation in inflammatory bowel diseases. 2014 , 15, 641-6		20
603	Microbial imbalance and intestinal pathologies: connections and contributions. 2014 , 7, 1131-42		65
602	Norovirus triggered microbiota-driven mucosal inflammation in interleukin 10-deficient mice. 2014 , 20, 431-43		105
601	Microbiome, inflammation, and cancer. 2014 , 20, 181-9		136
600	Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. 2014 , 20, 1217-26		19
599	Colonic expression of the peptide transporter PEPT1 is downregulated during intestinal inflammation and is not required for NOD2-dependent immune activation. 2014 , 20, 671-84		18
598	Physiologic TLR9-CpG-DNA interaction is essential for the homeostasis of the intestinal immune system. 2014 , 20, 136-43		13
597	Rodent intestinal epithelial carcinogenesis: pathology and preclinical models. 2014 , 42, 148-61		14

596	The Macrophage Transcriptome. 2014 , 559-585		1
595	Differential stimulation of peripheral blood mononuclear cells in Crohn's disease by fungal glycans. 2014 , 29, 1976-84		12
594	Control of intestinal inflammation by interleukin-10. 2014 , 380, 19-38		57
593	Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. 2014 , 7, 473-87		192
592	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. 2014 , 126, 7-19		192
591	Beneficial modulation of the gut microbiota. 2014 , 588, 4120-30		166
590	The role of short-chain fatty acids in health and disease. 2014 , 121, 91-119		953
589	The effect of intestinal alkaline phosphatase on intestinal epithelial cells, macrophages and chronic colitis in mice. 2014 , 100, 118-124		19
588	Inflammatory Bowel Diseases. 2014 , 873-888		
587	Attenuation of intestinal inflammation in interleukin-10-deficient mice infected with Citrobacter rodentium. <i>Infection and Immunity</i> , 2014 , 82, 1949-58	.7	24
587 586			125
	rodentium. <i>Infection and Immunity</i> , 2014 , 82, 1949-58 The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T		
586	rodentium. <i>Infection and Immunity</i> , 2014 , 82, 1949-58 The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. 2014 , 15, 571-9 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and		125
586 585	rodentium. <i>Infection and Immunity</i> , 2014 , 82, 1949-58 The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. 2014 , 15, 571-9 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. 2014 , 18, 402-14		125 89
586 585 584	The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. 2014, 15, 571-9 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. 2014, 18, 402-14 Emerging roles of the microbiome in cancer. 2014, 35, 249-55		125 89 156
586 585 584 583	The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. 2014, 15, 571-9 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. 2014, 18, 402-14 Emerging roles of the microbiome in cancer. 2014, 35, 249-55 Cytokine Frontiers. 2014,		125 89 156
586 585 584 583 582	The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. 2014, 15, 571-9 Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. 2014, 18, 402-14 Emerging roles of the microbiome in cancer. 2014, 35, 249-55 Cytokine Frontiers. 2014, Interplay between DNA repair and inflammation, and the link to cancer. 2014, 49, 116-39 Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory		125 89 156 12

578	Interleukin-10 in Health and Disease. 2014 ,		7
577	Macrophages: Biology and Role in the Pathology of Diseases. 2014 ,		8
576	IBD across the age spectrum: is it the same disease?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 88-98	24.2	139
575	Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. <i>Infection and Immunity</i> , 2014 , 82, 2239-46	3.7	77
574	Lack of interleukin-10-mediated anti-inflammatory signals and upregulated interferon gamma production are linked to increased intestinal epithelial cell apoptosis in pathogenic simian immunodeficiency virus infection. <i>Journal of Virology</i> , 2014 , 88, 13015-28	6.6	24
573	The molecular basis of IL-10 function: from receptor structure to the onset of signaling. 2014 , 380, 191-	212	72
572	IL-10 function, regulation, and in bacterial keratitis. 2014 , 30, 373-80		24
571	The vitamin D receptor turns off chronically activated T´cells. 2014 , 1317, 70-5		62
570	The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. 2014 , 49, 785-98		142
569	The effects of the microbiota on the host immune system. 2014 , 47, 494-504		32
568	Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. 2014 , 122, 177-210		175
567	The role of the adaptive immune system in regulation of gut microbiota. 2014 , 260, 67-75		86
566	Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. 2014 , 21, 15-25		212
565	Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. 2014 , 239, 1524-30		89
564	Diet, gut microbes, and genetics in immune function: can we leverage our current knowledge to achieve better outcomes in inflammatory bowel diseases?. 2014 , 31, 16-23		19
563	Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease. <i>Journal of Crohnus and Colitis</i> , 2014 , 8, 1551-6	1.5	24
562	A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. 2014 , 63, 1275-83		925
561	T-cell selection and intestinal homeostasis. 2014 , 259, 60-74		34

560	Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) mice. 2014 , 147, 667-679.e10		23
559	Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mousea model mimicking inflammatory bowel disease. <i>Journal of Crohnus and Colitis</i> , 2014 , 8, 147-60	1.5	29
558	Human intestinal spirochaetosis in two ulcerative colitis patients. 2014 , 53, 2067-71		11
557	The M1 and M2 paradigm of macrophage activation: time for reassessment. 2014 , 6, 13		2632
556	Correction of Microbiota Disturbances or Antagonism Against Specific Pathogens in IBD. 2014 , 238-259		
555	Commensal Intestinal Microbiota and Mucosal Immune System Development and Function. 2014,		
554	Role of emerging Campylobacter species in inflammatory bowel diseases. 2014 , 20, 2189-97		38
553	Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. 2014 , 93, e51		108
552	Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis. 2015 , 146, 359-68		28
551	Irsogladine Maleate Prevents Colitis in Interleukin-10 Gene-Deficient Mice by Reducing Interleukin-12 and -23 Production. 2015 , 38, 1681-8		2
550	Malabsorption. 2015 , 43-76		
549	Inflammation-associated microbiota in pediatric eosinophilic esophagitis. 2015 , 3, 23		95
548	Dendritic cell immunoreceptor 1 alters neutrophil responses in the development of experimental colitis. 2015 , 16, 64		11
547	Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. 2015 , 21, 963-72		97
546	A Multihit Model: Colitis Lessons from the Interleukin-10-deficient Mouse. 2015 , 21, 1967-75		128
545	Changes in composition of caecal microbiota associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. 2015 , 7, 1798-816		35
544	Intestinal Microbiota and the Innate Immune System - A Crosstalk in Crohn's Disease Pathogenesis. <i>Frontiers in Immunology</i> , 2015 , 6, 489	8.4	24
543	Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. <i>Frontiers in Immunology</i> , 2015 , 6, 555	8.4	51

(2015-2015)

542	The hygiene hypothesis: current perspectives and future therapies. 2015 , 4, 143-57	96
541	Osteopontin Deficiency Accelerates Spontaneous Colitis in Mice with Disrupted Gut Microbiota and Macrophage Phagocytic Activity. 2015 , 10, e0135552	17
540	Oral Manifestations of Crohn's Disease: A Case Report and Review of the Literature. 2015 , 2015, 830472	12
539	T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome. 2015 , 2015, 504638	31
538	Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. 2015 , 21, 11321-30	24
537	Resident bacteria-stimulated IL-10-secreting B cells ameliorate T cell-mediated colitis by inducing Tr-1 cells that require IL-27-signaling. 2015 , 1, 295-310	27
536	A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease. 2015 , 50, 928-39	81
535	Epithelial Cells: Structure, Transport, and Barrier Function. 2015 , 187-210	4
534	Discriminating Pathogens from Commensals at Mucosal Surfaces. 2015 , 975-984	5
533	Experimental Models of Gastrointestinal Inflammatory Diseases. 2015 , 1537-1549	
532	The Principles and Practice of Nutritional Support. 2015,	2
531	Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. 2015 , 21, 1674-82	102
530	Targeted 25-hydroxyvitamin D3 1 hydroxylase adoptive gene therapy ameliorates dss-induced colitis without causing hypercalcemia in mice. 2015 , 23, 339-51	22
529	Experimental Models of Inflammatory Bowel Diseases. 2015 , 1, 154-170	333
528	Telmisartan attenuates the inflamed mesenteric adipose tissue in spontaneous colitis by mechanisms involving regulation of neurotensin/microRNA-155 pathway. 2015 , 93, 461-9	14
527	The composition of the gut microbiota shapes the colon mucus barrier. 2015 , 16, 164-77	350
526	Metabonomics and Gut Microbiota in Nutrition and Disease. 2015,	2
525	Low prevalence of Blastocystis sp. in active ulcerative colitis patients. 2015 , 34, 1039-44	37

524	Genetically engineered mucin mouse models for inflammation and cancer. 2015 , 34, 593-609	14
523	B cells responses and cytokine production are regulated by their immune microenvironment. 2015 , 74, 318-26	171
522	Intestinales Mikrobiom und chronisch-entzfidliche Darmerkrankungen: Feindschaft oder Freundschaft?. 2015 , 10, 87-101	2
521	Proneness of TLR5 deficient mice to develop colitis is microbiota dependent. <i>Gut Microbes</i> , 2015 , 6, 279- 8 3	26
520	Maintaining intestinal health: the genetics and immunology of very early onset inflammatory bowel disease. 2015 , 1, 462-476	32
519	Topographical Mapping of the Rainbow Trout (Oncorhynchus mykiss) Microbiome Reveals a Diverse Bacterial Community with Antifungal Properties in the Skin. 2015 , 81, 6915-25	128
518	Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. 2014 , 16, 159-77	44
517	Deciphering the crosstalk among IL-1 and IL-10 family cytokines in intestinal immunity. 2015 , 36, 471-8	21
516	Induction of cellular and molecular immunomodulatory pathways by vitamin A and flavonoids. 2015 , 15, 1411-28	14
515	Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases. 2015 , 15, 39	12
514	Gnotobiotics. 2015 , 1263-1296	2
513	Differences between adults and children: genetics and beyond. 2015 , 9, 191-6	6
512	Substance P and the regulation of inflammation in infections and inflammatory bowel disease. 2015 , 213, 453-61	26
511	Transgenic Expression of Vitamin D Receptor in Gut Epithelial Cells Ameliorates Spontaneous Colitis Caused by Interleukin-10 Deficiency. 2015 , 60, 1941-7	25
510	Generation of outbred Ace2 knockout mice by RNA transfection of TALENs displaying colitis reminiscent pathophysiology and inflammation. 2015 , 24, 433-46	13
509	New developments in goblet cell mucus secretion and function. <i>Mucosal Immunology</i> , 2015 , 8, 712-9 9.2	321
508	Role of the Gut Microbiota in Maintaining GI Health: Highlights on Inflammatory Bowel Disease. 2015 , 261-310	
507	Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice. 2015 , 145, 1202-10	29

(2015-2015)

506	epithelial-macrophage crosstalk. 2015 , 7, 87-101		41
505	Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. <i>Mucosal Immunology</i> , 2015 , 8, 720-30	9.2	78
504	Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD. 2015 , 21, 400-8		68
503	Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. 2015 , 21, 139-53		79
502	Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice. 2015 , 21, 257-66		11
501	Depletion of enteroantigen-activated CD4+ T cells: effects on proliferation and pathogenicity. 2015 , 27, 419-24		1
500	Attenuation of Colitis by Serum-Derived Bovine Immunoglobulin/Protein Isolate in a Defined Microbiota Mouse Model. 2015 , 60, 3293-303		26
499	Stereomicroscopic 3D-pattern profiling of murine and human intestinal inflammation reveals unique structural phenotypes. 2015 , 6, 7577		41
498	Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium. 2015 , 112, E4264-71		22
497	Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?. 2015 , 30, 760-79		44
496	Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases. 2015 , 149, 1265-1274.	e3	45
495	Inflammation neither increases hepatic hepcidin nor affects intestinal (59)Fe-absorption in two murine models of bowel inflammation, hemizygous TNF(ARE/+) and homozygous IL-10(-/-) mice. 2015 , 32, 162-7		3
494	Intestinal microbiota and ulcerative colitis. 2015 , 21, 761-8		69
493	Aggravation of Established Colitis in Specific Pathogen-free IL-10 Knockout Mice by Restraint Stress Is Not Mediated by Increased Colonic Permeability. <i>Journal of Crohnus and Colitis</i> , 2015 , 9, 754-62	1.5	8
492	A Review of Applied Aspects of Dealing with Gut Microbiota Impact on Rodent Models. 2015 , 56, 250-64		22
491	Manipulating the Gut Microbiota: Methods and Challenges. 2015 , 56, 205-17		69
490	The Intestinal Microbiota in Inflammatory Bowel Disease. 2015 , 56, 192-204		111
489	Vitamin D receptor pathway is required for probiotic protection in colitis. 2015 , 309, G341-9		65

488	The dual nature of interleukin-10 in pemphigus vulgaris. 2015 , 73, 335-41		21
487	Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. 2015, 64, 1082-	94	195
486	Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells. <i>Mucosal Immunology</i> , 2015 , 8, 265-78	9.2	154
485	Commensal Gram-positive bacteria initiates colitis by inducing monocyte/macrophage mobilization. <i>Mucosal Immunology</i> , 2015 , 8, 152-60	9.2	65
484	Recent Advances and Understanding of Using Probiotic-Based Interventions to Restore Homeostasis of the Microbiome for the Prevention/Therapy of Bacterial Diseases. 2016 , 823-841		1
483	11. Chronisch entzEdliche Darmerkrankungen und gastrointestinale Mikrobiota. 2016 ,		
482	Role of antibiotics for treatment of inflammatory bowel disease. 2016 , 22, 1078-87		122
481	Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjgren's syndrome. 2016 , 59, 107-112		10
480	Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model. 2016 , 2016, 4953120		13
479	Pathogenic role of the gut microbiota in gastrointestinal diseases. 2016 , 14, 127-38		86
478	Postbiotic Modulation of Retinoic Acid Imprinted Mucosal-like Dendritic Cells by Probiotic Lactobacillus reuteri 17938 In Vitro. <i>Frontiers in Immunology</i> , 2016 , 7, 96	8.4	40
477	Carrageenan Gum and Adherent Invasive Escherichia coli in a Piglet Model of Inflammatory Bowel Disease: Impact on Intestinal Mucosa-associated Microbiota. 2016 , 7, 462		34
476	Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. 2016 , 12, 217		13
475	. 2016,		8
474	Distinct Microbiotas are Associated with Ileum-Restricted and Colon-Involving Crohn's Disease. 2016 , 22, 293-302		36
473	Inhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice. 2016 , 22, 841-52		17
472	Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. 2016 , 22, 1157-67		75
471	Recent Advances and Understanding of Using Probiotic-Based Interventions to Restore Homeostasis of the Microbiome for the Prevention/Therapy of Bacterial Diseases. 2016 , 4,		8

470 Microbes, Metabolites and Health. **2016**, 13-48

469	Elucidating the Role of the Interleukin-10 Receptor in Mucosal Inflammation Uncovers a Potential Treatment for Infantile Inflammatory Bowel Disease. 2016 , 151, 1061-1062		
468	Dissecting the Interplay Between Intestinal Microbiota and Host Immunity in Health and Disease: Lessons Learned from Germfree and Gnotobiotic Animal Models. 2016 , 6, 253-271		82
467	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. <i>Scientific Reports</i> , 2016 , 6, 35014	4.9	33
466	Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. <i>Journal of Crohnus and Colitis</i> , 2016 , 10, 943-52	1.5	83
465	Gut microbiota, metabolites and host immunity. 2016 , 16, 341-52		1324
464	Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice. 2016 , 2, 468-481		123
463	Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. 2016 , 19, 455-69		144
462	A Disease-Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel Disease Patients. 2016 , 2, 750-766		103
461	Regulation of Cytokine Gene Expression in Immunity and Diseases. 2016 ,		3
460	Salmonella Protein AvrA Activates the STAT3 Signaling Pathway in Colon Cancer. 2016 , 18, 307-316		48
459	Regulation of Interleukin-10 Expression. 2016 , 941, 89-116		66
458	Inflammatory bowel disease and the gut microbiota. 2016 , 301-315		
457	Acute severe ulcerative colitis: from pathophysiology to clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 654-664	24.2	80
456	Differential Production of Type I IFN Determines the Reciprocal Levels of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BALB/c Macrophages. 2016 , 197, 2838-53		28
455	Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. 2016 , 1029-1030, 88-94		36
454	The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. 2016 , 51, 1407-1415		116
453	- Nutrigenetics and Crohn⊠ Disease. 2016 , 172-187		

452	Gut microbiota in autoimmunity: potential for clinical applications. 2016 , 39, 1565-1576	35
45 ¹	Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review. 2016 , 25, 511-522	162
450	Integrin CD11b attenuates colitis by strengthening Src-Akt pathway to polarize anti-inflammatory IL-10 expression. <i>Scientific Reports</i> , 2016 , 6, 26252	17
449	Helicobacter bilis Infection Alters Mucosal Bacteria and Modulates Colitis Development in Defined Microbiota Mice. 2016 , 22, 2571-2581	8
448	Antibiotic Treatment Induces Long-lasting Changes in the Fecal Microbiota that Protect Against Colitis. 2016 , 22, 2328-40	14
447	A Single Species of Clostridium Subcluster XIVa Decreased in Ulcerative Colitis Patients. 2016 , 22, 2802-2810	66
446	MAG-EPA reduces severity of DSS-induced colitis in rats. 2016 , 310, G808-21	13
445	Mouse models of intestinal inflammation and cancer. 2016 , 90, 2109-2130	12
444	Function of the glycosyltransferase GnT-V in colitis. 2016 , 51, 406-8	
443	Helicobacter saguini, a Novel Helicobacter Isolated from Cotton-Top Tamarins with Ulcerative Colitis, Has Proinflammatory Properties and Induces Typhlocolitis and Dysplasia in Gnotobiotic 3.7 IL-10-/- Mice. <i>Infection and Immunity</i> , 2016 , 84, 2307-2316	15
442	Alterations to chromatin in intestinal macrophages link IL-10 deficiency to inappropriate inflammatory responses. 2016 , 46, 1912-25	24
441	Methods of Inducing Inflammatory Bowel Disease in Mice. 2016 , 72, 5.58.1-5.58.42	18
440	Transient activation of mucosal effector immune responses by resident intestinal bacteria in normal hosts is regulated by interleukin-10 signalling. 2016 , 148, 304-14	12
439	Targeting JAK kinase in solid tumors: emerging opportunities and challenges. 2016 , 35, 939-51	143
438	Role of Collagen Conduit With Duloxetine and/or Pregabalin in the Management of Partial Peripheral Nerve Injury. 2016 , 74, 1120-30	10
437	The Role of Neuropeptides in Mouse Models of Colitis. 2016 , 59, 203-10	18
436	Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis. 2016 , 94, 545-56	30
435	The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. 2016 , 30, 87-93	72

434	Investigating a holobiont: Microbiota perturbations and transkingdom networks. <i>Gut Microbes</i> , 2016 , 7, 126-35	8.8	26
433	An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?. 2016 , 34, 64-71		12
432	Sulfide as a Mucus Barrier-Breaker in Inflammatory Bowel Disease?. 2016 , 22, 190-199		127
431	Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD). 2016 , 131-147		2
430	Nutritional Management of Inflammatory Bowel Diseases. 2016 ,		2
429	Antibiotic-treated versus germ-free rodents for microbiota transplantation studies. <i>Gut Microbes</i> , 2016 , 7, 68-74	8.8	74
428	Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. <i>Journal of Crohnus and Colitis</i> , 2016 , 10, 387-94	1.5	183
427	Host and microbiota interactions are critical for development of murine Crohn's-like ileitis. <i>Mucosal Immunology</i> , 2016 , 9, 787-97	9.2	25
426	Changes in Foxp3-Positive Regulatory T Cell Number in the Intestine of Dogs With Idiopathic Inflammatory Bowel Disease and Intestinal Lymphoma. 2016 , 53, 102-12		35
425	Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. 2016 , 65, 944-53		49
424	Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. 2016 , 65, 225-37		220
423	The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease. <i>Gut Microbes</i> , 2017 , 8, 359-365	8.8	26
422	Mucosal immune tolerance at the ocular surface in health and disease. 2017 , 150, 397-407		32
421	Serotonin disturbs colon epithelial tolerance of commensal E. coli by increasing NOX2-derived superoxide. 2017 , 106, 196-207		29
420	IL-10 Plays Opposing Roles during Systemic and Localized Infections. 2017 , 198, 2352-2365		46
419	Indigo Naturalis Ameliorates Oxazolone-Induced Dermatitis but Aggravates Colitis by Changing the Composition of Gut Microflora. 2017 , 173, 23-33		11
418	The role of the microbiome in cancer development and therapy. 2017 , 67, 326-344		277
417	NLRP6 Protects Il10 Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. 2017 , 19, 733-745		156

416	Dietary Salt Exacerbates Experimental Colitis. 2017, 199, 1051-1059		37
415	Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype. <i>Journal of Crohnus and Colitis</i> , 2017 , 11, 1247-1257	1.5	18
414	The gut bacterium and pathobiont Bacteroides vulgatus activates NF- B in a human gut epithelial cell line in a strain and growth phase dependent manner. 2017 , 47, 209-217		40
413	The Composition of Colonic Commensal Bacteria According to Anatomical Localization in Colorectal Cancer. 2017 , 3, 90-97		19
412	Primary Sclerosing Cholangitis (PSC): Current Concepts in Biology and Strategies for New Therapy. 2017 , 183-218		
411	Early-life antibiotic treatment enhances the pathogenicity of CD4 T cells during intestinal inflammation. 2017 , 101, 893-900		19
410	Guillain Barr Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics. 2017 , 77, 11-38		21
409	Using murine colitis models to analyze probiotics-host interactions. 2017 , 41, S49-S70		23
408	Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. 2017 , 279, 70-89		515
407	Sulfate-reducing bacteria stimulate gut immune responses and contribute to inflammation in experimental colitis. 2017 , 189, 29-38		47
406	Development of Inflammatory Bowel Disease Is Linked to a Longitudinal Restructuring of the Gut Metagenome in Mice. 2017 , 2,		33
405	S100A4 contributes to colitis development by increasing the adherence of Citrobacter rodentium in intestinal epithelial cells. <i>Scientific Reports</i> , 2017 , 7, 12099	4.9	14
404	Interleukin-4 and Interleukin-10 Gene Polymorphisms in Patients with Inflammatory Bowel Disease. 2017 , 46, 714-729		21
403	Dietary Broccoli Impacts Microbial Community Structure and Attenuates Chemically Induced Colitis in Mice in an Ah receptor dependent manner. 2017 , 37, 685-698		38
402	Hydrodynamic IL10 Gene Transfer in Human Colon: Results from an "EX VIVO" Study with Potential Clinical Application in Crohn's Disease. 2017 , 23, 1360-1370		1
401	Murine models for mucosal tolerance in allergy. 2017 , 30, 12-27		10
400	Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis. 2017 , 8, 1896		96
399	Changes in the Qualitative and Quantitative Composition of the Intestinal Microflora in Rats in Experimental Allergic Encephalomyelitis. 2017 , 47, 328-336		

(2017-2017)

398	Peripartum Antibiotics Promote Gut Dysbiosis, Loss of Immune Tolerance, and Inflammatory Bowel Disease in Genetically Prone Offspring. 2017 , 20, 491-504	69
397	An exposome perspective: Early-life events and immune development in a changing world. 2017 , 140, 24-40	101
396	The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond. 2017 , 33, 153-162	5
395	Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis. 2017 , 9, 71-80	13
394	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. 2017 , 30, 191-231	41
393	Repression of MicroRNA Function Mediates Inflammation-associated Colon Tumorigenesis. 2017 , 152, 631-643	18
392	The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis. 2017 , 61, 51-59	36
391	Interaction of gut microbiota with bile acid metabolism and its influence on disease states. 2017 , 101, 47-64	235
390	Microbial, metabolomic, and immunologic dynamics in a relapsing genetic mouse model of colitis induced by T-synthase deficiency. <i>Gut Microbes</i> , 2017 , 8, 1-16	34
389	Faecal transplantation for IBD management-pitfalls and promises. 2017 , 124, 181-190	4
388	47 Years of IAI: a Glance in the Mirror and the Road Ahead. <i>Infection and Immunity</i> , 2017 , 85, 3.7	
387	A gut pathobiont synergizes with the microbiota to instigate inflammatory disease marked by immunoreactivity against other symbionts but not itself. <i>Scientific Reports</i> , 2017 , 7, 17707	27
386	Macrophage dysfunction initiates colitis during weaning of infant mice lacking the interleukin-10 receptor. 2017 , 6,	16
385	Differing Complex Microbiota Alter Disease Severity of the IL-10 Mouse Model of Inflammatory Bowel Disease. 2017 , 8, 792	28
384	Phospholipase A of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A Inhibitors. 2018 , 2, 180-187	8
383	IL-10: A Multifunctional Cytokine in Viral Infections. 2017 , 2017, 6104054	163
382	Gnotobiotics and Inflammatory Bowel Disease. 2017 , 391-409	
381	Translating our microbiome into medicine. 2017 , 206, 287-288	

380	Polysaccharides from Ramat ameliorate colitis rats by modulating the intestinal microbiota community. 2017 , 8, 80790-80803	46
379	Potential role of nutraceutical compounds in inflammatory bowel disease. 2017 , 23, 2483-2492	44
378	The Gastrointestinal Microbiome: A Review. 2018 , 32, 9-25	248
377	Aronia berry (Aronia mitschurinii ☑iking〗inhibits colitis in mice and inhibits T cell tumour necrosis factor-Becretion. 2018 , 44, 48-57	13
376	Murine EHerpesvirus 68 Induces Severe Lung Inflammation in IL-27-Deficient Mice with Liver Dysfunction Preventable by Oral Neomycin. 2018 , 200, 2703-2713	2
375	Microbial Eukaryotes: a Missing Link in Gut Microbiome Studies. 2018, 3,	55
374	Intestinal IFN-Eproducing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease. 2018 , 142, 1537-1547.e8	44
373	Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflammation by Suppressing Intestinal Epithelial Cell Apoptosis. 2018 , 159, 967-979	51
372	Regional Control of Regulatory Immune Cells in the Intestine. 2018 , 6, 29-34	4
371	Essential immunologic orchestrators of intestinal homeostasis. 2018 , 3,	37
370	The Hypoxia-Adenosine Link during Intestinal Inflammation. 2018 , 200, 897-907	26
369	The role of the gut microbiome in systemic inflammatory disease. 2018 , 360, j5145	202
368	IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4 T Cell Migration. 2018 , 200, 1580-1592	6
367	Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach. 2018 ,	5
366	Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists. 2018 , 131, 1017-102	249
365	Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. 2018 , 30, 275-296	64
364	Gut colonization with extended-spectrum flactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis. 2018 , 30, 92-100	5
363	Bifidobacteria alleviate experimentally induced colitis by upregulating indoleamine 2, 3-dioxygenase expression. 2018 , 62, 71-79	9

(2018-2018)

362	Short-Chain Fatty Acids Suppress Inflammatory Reactions in Caco-2 Cells and Mouse Colons. 2018 , 66, 108-117		37	
361	Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. 2018 , 192, 173-182		56	
360	The role of Blastocystis hominis in the activation of ulcerative colitis. 2019 , 30, 40-46		10	
359	Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. 2018 , 12, 17-29		62	
358	Dysbiosis of the Gut Microbiota on the Inflammatory Background due to Lack of Suppressor of Cytokine Signalling-1 in Mice. 2019 , 3, 145-154		2	
357	Contribution of sulfate-reducing bacteria to homeostasis disruption during intestinal inflammation. 2018 , 215, 145-151		15	
356	The Probiotic Effectiveness in Preventing Experimental Colitis Is Correlated With Host Gut Microbiota. 2018 , 9, 2675		12	
355	Manipulating gut microbiota using faecal microbiome transplantation: update on evidence and guide for use. 2018 , 16, 43-49			
354	Microbiota control acute arterial inflammation and neointimal hyperplasia development after arterial injury. 2018 , 13, e0208426		12	
353	Antimicrobial peptide LL-37 forms complex with bacterial DNA to facilitate blood translocation of bacterial DNA and aggravate ulcerative colitis. 2018 , 63, 1364-1375		4	
352	Environmental Factors Modify the Severity of Acute DSS Colitis in Caspase-11-Deficient Mice. 2018 , 24, 2394-2403		7	
351	Mouse Gamma Herpesvirus MHV-68 Induces Severe Gastrointestinal (GI) Dilatation in Interferon Gamma Receptor-Deficient Mice (IFNR) That Is Blocked by Interleukin-10. 2018 , 10,		3	
350	Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. 2018 , 9, 961		31	
349	The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. 2018 , 132, 2013-2028		24	
348	Pathogen- and Microbial- Associated Molecular Patterns (PAMPs/MAMPs) and the Innate Immune Response in Crohn Disease. 2018 , 175-187		4	
347	The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. 2018 , 6,		41	
346	The interplay between microbes and the immune response in inflammatory bowel disease. 2018 , 596, 3869-3882		25	
345	The role of diet in the aetiopathogenesis of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 525-535	24.2	92	

344	Colonic Inhibition of Phosphatase and Tensin Homolog Increases Colitogenic Bacteria, Causing Development of Colitis in Il10-/- Mice. 2018 , 24, 1718-1732	9
343	Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease. 2018 , 8, 731-760	6
342	A Synbiotic with Tumor Necrosis Factor- Inhibitory Activity Ameliorates Experimental Jejunoileal Mucosal Injury. 2018 , 2018, 9184093	2
341	Microbial Physiology of the Digestive Tract and Its Role in Inflammatory Bowel Diseases. 2018 , 795-810	4
340	Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform. 2018 , 13, e0196950	9
339	Cathelicidin in Gastrointestinal Disorders. 2018 , 61-76	
338	Microbiome and Diseases: Inflammatory Bowel Diseases. 2018 , 151-174	
337	Microbiome and Diseases: Colorectal Cancer. 2018 , 231-249	2
336	Reduced peripheral blood regulatory B cell levels are not associated with the Expanded Disability Status Scale score in multiple sclerosis. 2018 , 46, 3970-3978	6
335	Bacterial Signaling at the Intestinal Epithelial Interface in Inflammation and Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 1927	34
334	Invariant Natural Killer T Cells Shape the Gut Microbiota and Regulate Neutrophil Recruitment and Function During Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2018 , 9, 999	14
333	Persistent serovar Typhimurium Infection Increases the Susceptibility of Mice to Develop Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2018 , 9, 1166	23
332	The Inner Workings of the Outer Surface: Skin and Gill Microbiota as Indicators of Changing Gut Health in Yellowtail Kingfish. 2017 , 8, 2664	59
331	Expanded TCRICDR3 clonotypes distinguish Crohn's disease and ulcerative colitis patients. Mucosal Immunology, 2018, 11, 1487-1495 9.2	10
330	Polyphenolic derivatives from mango (Mangifera Indica L.) modulate fecal microbiome, short-chain fatty acids production and the HDAC1/AMPK/LC3 axis in rats with DSS-induced colitis. 2018 , 48, 243-251	26
329	E(1,3)-Glucan derived from induces inflammatory cytokines from macrophages and lamina propria mononuclear cells derived from patients with Crohn's disease. 2018 , 16, 384-392	3
328	The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. 2018 , 8, 299	22
327	Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis. 2018 , 53, 1031-1042	26

326	(NOD) Mouse Is Associated With Alterations of Gut Microbiota and Immune Homeostasis. 2018 , 165, 291-301		12
325	Early life stress in mice is a suitable model for Irritable Bowel Syndrome but does not predispose to colitis nor increase susceptibility to enteric infections. 2018 , 73, 403-415		21
324	Microbial dysbiosis associated with impaired intestinal Na/H exchange accelerates and exacerbates colitis in ex-germ free mice. <i>Mucosal Immunology</i> , 2018 , 11, 1329-1341	9.2	26
323	Infection of the Small Intestine Induces Chronic Colitis in Genetically Susceptible Hosts. 2018 , 201, 548-	559	19
322	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. 2018 , 197-288		
321	Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. 2019 , 8,		217
320	The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors. <i>Microorganisms</i> , 2019 , 7,	4.9	87
319	Gut dysbiosis and its epigenomic impact on disease. 2019 , 409-422		1
318	Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis.		15
317	2019 , 13, 1792-1804 Composition of the Intestinal Microbiota Determines the Outcome of Virus-Triggered Colitis in Mice. <i>Frontiers in Immunology</i> , 2019 , 10, 1708	8.4	22
316	Alleviation of Intestinal Inflammation by Oral Supplementation With 2-Fucosyllactose in Mice. 2019 , 10, 1385		28
315	The effects of prebiotics on growth performance and in vitro immune biomarkers in weaned pigs. 2019 , 3, 1315-1325		6
314	Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience. 2019 , 44, 101325		14
313	Functions and regulation of T cell-derived interleukin-10. 2019 , 44, 101344		48
312	Introducing Murine Microbiome Database (MMDB): A Curated Database with Taxonomic Profiling of the Healthy Mouse Gastrointestinal Microbiome. <i>Microorganisms</i> , 2019 , 7,	4.9	9
311	Combination of Cannabinoids, B - Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. <i>Frontiers in Immunology</i> , 2019 , 10, 1921	8.4	38
310	Cancer Biomarkers in Body Fluids. 2019 ,		1
309	The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice. 2019 , 14, e0221618		6

308	Dietary cranberry suppressed colonic inflammation and alleviated gut microbiota dysbiosis in dextran sodium sulfate-treated mice. 2019 , 10, 6331-6341	34
307	Cesarean section increases sensitivity to oxazolone-induced colitis in C57BL/6 mice. <i>Mucosal Immunology</i> , 2019 , 12, 1348-1357	8
306	Phosphoinositide 3-Kinase P110E ignaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. 2019 , 8,	10
305	Escherichia coli promotes DSS-induced murine colitis recovery through activation of the TLR4/NF-B signaling pathway. 2019 , 19, 2021-2028	2
304	The Super-Donor Phenomenon in Fecal Microbiota Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019 , 9, 2	152
303	The Crohn's disease polymorphism, T300A, alters the gut microbiota and enhances the local Th1/Th17 response. 2019 , 8,	50
302	Intestinal parasitic infection alters bacterial gut microbiota in children. 2019 , 7, e6200	23
301	ER stress abrogates the immunosuppressive effect of IL-10 on human macrophages through inhibition of STAT3 activation. 2019 , 68, 775-785	5
300	Microbial genes and pathways in înflammatory bowel disease. 2019 , 17, 497-511	187
299	The Microbiota and the Immune Response: What Is the Chicken and What Is the Egg?. 2019 , 29, 381-393	21
298	Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease. 2019, 47, 21-31	16
297	Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. <i>Mucosal Immunology</i> , 2019 , 9.2 12, 1150-1163	28
296	Immunobiotics Beneficially Modulate TLR4 Signaling Triggered by Lipopolysaccharide and Reduce Hepatic Steatosis In Vitro. 2019 , 2019, 3876896	9
295	Fluid supplementation accelerates epithelial repair during chemical colitis. 2019 , 14, e0215387	4
294	[Ulcerative colitis: Does the modulation of gut microbiota induce long-lasting remission?]. 2019, 57, 834-842	4
293	Intestinal Organoids as a Novel Complementary Model to Dissect Inflammatory Bowel Disease. 2019 , 2019, 8010645	6
292	Role of inulin as prebiotics on inflammatory bowel disease. 2019 , 13, 1-8	42
291	The Use of Defined Microbial Communities To Model Host-Microbe Interactions in the Human Gut. 2019 , 83,	37

290	Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. 2019, 199, 164	l-172	28
289	Antibiotics exacerbated colitis by affecting the microbiota, Treg cells and SCFAs in IL10-deficient mice. <i>Biomedicine and Pharmacotherapy</i> , 2019 , 114, 108849	7.5	12
288	Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8 T-Cell Activation. <i>Frontiers in Immunology</i> , 2019 , 10, 486	8.4	7
287	Mouse Models of Innate Immunity. 2019,		1
286	The Azoxymethane/Il10 Model of Colitis-Associated Cancer (CAC). 2019, 1960, 215-225		3
285	Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice. <i>Gut Microbes</i> , 2019 , 10, 578-598	8.8	21
284	Macrophage-dependent neutrophil recruitment is impaired under conditions of increased intestinal permeability in JAM-A-deficient mice. <i>Mucosal Immunology</i> , 2019 , 12, 668-678	9.2	18
283	Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. 2019 , 35, 45		9
282	c-Maf-dependent T cell control of intestinal T17 cells and IgA establishes host-microbiota homeostasis. 2019 , 20, 471-481		7 ²
281	Intestinal microbes direct CXCR1 cells to balance intestinal immunity. <i>Gut Microbes</i> , 2019 , 10, 540-546	8.8	2
280	Interleukin-37 Inhibits Colon Carcinogensis During Chronic Colitis. <i>Frontiers in Immunology</i> , 2019 , 10, 2632	8.4	5
279	Effects of probiotics and prebiotics on intestinal microbiota in mice with acute colitis based on 16S rRNA gene sequencing. 2019 , 132, 1833-1842		27
278	Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. 2019 , 98, e15718		12
277	The Gut Microbiome in Inflammatory Bowel Diseases: Diagnostic and Therapeutic Implications. 2019 , 35, 332-337		1
276	Monocyte and Alveolar Macrophage Skewing Is Associated with the Development of Pulmonary Arterial Hypertension in a Primate Model of HIV Infection. 2019 , 35, 63-74		9
275	Phenotypic Characterization of Very Early-Onset Inflammatory Bowel Disease with Interleukin-10 Signaling Deficiency: Based on a Large Cohort Study. 2019 , 25, 756-766		20
274	Murine Adherent and Invasive E. coli Induces Chronic Inflammation and Immune Responses in the Small and Large Intestines of Monoassociated IL-10-/- Mice Independent of Long Polar Fimbriae Adhesin A. 2019 , 25, 875-885		17
273	Zero tolerance! A perspective on monogenic disorders with defective regulatory T cells and IBD-like disease. 2019 , 287, 236-240		11

272	PPARlagonist enhances colitis-associated colorectal cancer. 2019 , 842, 248-254		16
271	Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. <i>Gut Microbes</i> , 2019 , 10, 334-357	8.8	53
270	Nod2 influences microbial resilience and susceptibility to colitis following antibiotic exposure. <i>Mucosal Immunology</i> , 2019 , 12, 720-732	9.2	21
269	Akkermansia muciniphila strain ATCC BAA-835 does not promote short-term intestinal inflammation in gnotobiotic interleukin-10-deficient mice. <i>Gut Microbes</i> , 2019 , 10, 188-203	8.8	22
268	Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. 2019 , 11,		67
267	Dietary iron variably modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice. <i>Gut Microbes</i> , 2020 , 11, 32-50	8.8	19
266	Validation studies for germ-free mice as a bio-assay to test the causative role of fecal microbiomes in IBD. <i>Gut Microbes</i> , 2020 , 11, 21-31	8.8	3
265	Environmental Microbial Factors Determine the Pattern of Inflammatory Lesions in a Murine Model of Crohn's Disease-Like Inflammation. 2020 , 26, 66-79		12
264	The development of colitis in Il10 mice is dependent on IL-22. <i>Mucosal Immunology</i> , 2020 , 13, 493-506	9.2	16
263	Impact of dietary manganese on experimental colitis in mice. 2020 , 34, 2929-2943		15
262	Triclocarban Exposure Exaggerates Spontaneous Colonic Inflammation in Il-10-/- Mice. 2020 , 174, 92-99)	11
261	Dietary resveratrol attenuated colitis and modulated gut microbiota in dextran sulfate sodium-treated mice. 2020 , 11, 1063-1073		34
2 60	Pyruvate dehydrogenase kinase is a negative regulator of interleukin-10 production in macrophages. 2020 , 12, 543-555		10
259	Gut microbiota and immunology of the gastrointestinal tract. 2020 , 63-78		1
258	Prescription Opioids induce Gut Dysbiosis and Exacerbate Colitis in a Murine Model of Inflammatory Bowel Disease. <i>Journal of Crohnus and Colitis</i> , 2020 , 14, 801-817	1.5	9
257	Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease. 2020 , 199, 24-38		20
256	The human microbiome in the 21 century. 2020 , 11, 5256		13
255	Physical Activity Shapes the Intestinal Microbiome and Immunity of Healthy Mice but Has No Protective Effects against Colitis in MUC2 Mice. 2020 , 5,		5

(2020-2020)

254	Dietary Emulsifiers Directly Impact Adherent-Invasive E. coli Gene Expression to Drive Chronic Intestinal Inflammation. 2020 , 33, 108229	22
253	Oral exposure to bisphenols induced food intolerance and colitis in vivo by modulating immune response in adult mice. 2020 , 146, 111773	2
252	Probiotic Lactobacillus and Bifidobacterium Strains Counteract Adherent-Invasive (AIEC) Virulence and Hamper IL-23/Th17 Axis in Ulcerative Colitis, but Not in Crohn's Disease. 2020 , 9,	15
251	Intestinal Inflammation Induced by Soybean Meal Ingestion Increases Intestinal Permeability and Neutrophil Turnover Independently of Microbiota in Zebrafish. <i>Frontiers in Immunology</i> , 2020 , 11, 1330 ^{8.4}	9
250	Roles of intestinal in human health and diseases. 2021 , 61, 3518-3536	14
249	A single early-in-life antibiotic course increases susceptibility to DSS-induced colitis. 2020 , 12, 65	12
248	Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. <i>Frontiers in Immunology</i> , 2020 , 11, 571731	70
247	Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice. 2020 , 12,	46
246	In Vitro Characterization of Gut Microbiota-Derived Commensal Strains: Selection of Strains Alleviating TNBS-Induced Colitis in Mice. 2020 , 9,	15
245	The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. <i>Frontiers in Immunology</i> , 2020 , 11, 1794	8
244	Autotaxin loss accelerates intestinal inflammation by suppressing TLR4-mediated immune responses. 2020 , 21, e49332	5
243	Intestinal Microbes in Autoimmune and Inflammatory Disease. Frontiers in Immunology, 2020 , 11, 59796&.4	13
242	Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. 2020 , 12,	15
241	The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. 2020 , 9,	46
240	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. 2020, 12,	19
239	AMPK is essential for IL-10 expression and for maintaining balance between inflammatory and cytoprotective signaling. 2020 , 1864, 129631	5
238	Relationship between T cells and microbiota in health and disease. 2020 , 171, 95-129	1
237	Loricrin: Past, Present, and Future. 2020 , 21,	14

236	Strategies to Dissect Host-Microbial Immune Interactions That Determine Mucosal Homeostasis vs. Intestinal Inflammation in Gnotobiotic Mice. <i>Frontiers in Immunology</i> , 2020 , 11, 214	8.4	10
235	Vitamin D Receptor Protects Against Dysbiosis and Tumorigenesis via the JAK/STAT Pathway in Intestine. 2020 , 10, 729-746		18
234	Epithelial Toll-like receptors and their role in gut homeostasis and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 263-278	24.2	118
233	Repertoire analysis of memory T-cell receptors in Japanese patients with inflammatory bowel disease. 2020 , 4, 624-631		2
232	Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. 2020 , 65, 757-788		52
231	Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of Lynch syndrome. 2020 , 147, 2316-2326		10
230	Gut microbiota in chronic inflammatory disorders: A focus on pediatric inflammatory bowel diseases and juvenile idiopathic arthritis. 2020 , 215, 108415		12
229	Regulation of Il-10 gene expression by Il-6 via Stat3 in grass carp head kidney leucocytes. 2020 , 741, 144	1579	8
228	Inflammatory bowel disease: A key role for microbiota?. 2020 , 25, 100713		5
227	A Novel PAK1-Notch1 Axis Regulates Crypt Homeostasis in Intestinal Inflammation. 2021 , 11, 892-907.e	1	3
226	Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications. 2021 , 140, 703-708		3
225	Gut microbiota shape the inflammatory response in mice with an epithelial defect. <i>Gut Microbes</i> , 2021 , 13, 1-18	8.8	1
224	Dysbiotic microbiota interactions in Crohn's disease. <i>Gut Microbes</i> , 2021 , 13, 1949096	8.8	5
223	Temporal Dynamics of Chronic Inflammation on the Cecal Microbiota in IL-10 Mice. <i>Frontiers in Immunology</i> , 2020 , 11, 585431	8.4	1
222	Role of Probiotics and Their Metabolites in Inflammatory Bowel Diseases (IBDs). 2021 , 12, 56-66		8
221	IL-10 driven memory T cell survival and Tfh differentiation promote HIV persistence.		2
220	Mutation spectrum of NOD2 reveals recessive inheritance as a main driver of Early Onset Crohn's Disease. <i>Scientific Reports</i> , 2021 , 11, 5595	4.9	11
219	Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. 2021,		2

218	Interleukin 10 and interleukin 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson. 2021 , 18, 13		3
217	The gut microbiome of laboratory mice: considerations and best practices for translational research. 2021 , 32, 239-250		6
216	The microbiome and rodent models of immune mediated diseases. 2021 , 32, 251-262		3
215	Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection. <i>Infection and Immunity</i> , 2021 , 89,	3.7	3
214	Impact of dietary sulfolipid-derived sulfoquinovose on gut microbiota composition and inflammatory status of colitis-prone interleukin-10-deficient mice. 2021 , 311, 151494		1
213	Comorbid Inflammatory Diseases of Digestive System and Eye. 2021 , 18, 20-29		
212	Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis. 2021 , 1		2
211	The brain-gut axis, inflammatory bowel disease and bioelectronic medicine. 2021 , 33, 349-356		2
210	A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. 2021 , 42, 1603990		6
209	Diet-Microbiota Interactions in Inflammatory Bowel Disease. 2021 , 13,		8
208	Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease. 2021 , 1		1
207	Early-Life Exposure to Antibiotics and Risk for Crohn's Disease: A Nationwide Danish Birth Cohort Study. 2021 ,		Ο
206	It takes a village: microbiota, parainflammation, paligenosis and bystander effects in colorectal cancer initiation. 2021 , 14,		1
205	Inflammatory bowel disease and the gut microbiota. 2021 , 1-11		1
204	Protective effects of different strains against lipopolysaccharide-induced acute intestinal injury, and their underlying functional genes 2022 , 36, 27-37		6
203	Reshaping of bacterial molecular hydrogen metabolism contributes to the outgrowth of commensal during gut inflammation. 2021 , 10,		2
202	Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD). 2021 , 14,		1
201	Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. 2021 , 54, 779-791		2

200	PIR-B Regulates CD4 IL17a T-Cell Survival and Restricts T-Cell-Dependent Intestinal Inflammatory Responses. 2021 , 12, 1479-1502		О
199	IL-10 Receptor Neutralization-Induced Colitis in Mice: A Comprehensive Guide. 2021 , 1, e227		1
198	Rules of Engagement: Epithelial-Microbe Interactions and Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2021 , 8, 669913	4.9	2
197	Beyond Immunity: Underappreciated Functions of Intestinal Macrophages. <i>Frontiers in Immunology</i> , 2021 , 12, 749708	8.4	6
196	Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C. 2021 , 218,		0
195	Colonizing Microbes, IL-10 and IL-22: Keeping the Peace at the Mucosal Surface. 2021 , 12, 729053		1
194	Gut microbiota and the immune system and inflammation. 2021 , 311-333		
193	Microbiology and Microbiome. 2021 , 77-104		
192	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. 5, 262-270		27
191	Experimental mouse models of inflammatory bowel disease: new insights into pathogenic mechanisms. 2003 , 67-99		2
190	The normal intestinal mucosa: a state of Bontrolled inflammation D2003, 101-120		9
189	The mucosal inflammatory response. Cytokines and chemokines. 2003 , 147-176		1
188	Endothelial and epithelial barriers in graft-versus-host disease. 2012 , 763, 105-31		9
187	Recent progress in engineering human-associated microbiomes. 2014 , 1151, 3-25		12
186	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. 2011 , 123-150		2
185	Bacterial mediated gastrointestinal inflammation. 2013 , 1031, 197-202		1
184	Interleukin-10: Cytokines in Anti-inflammation and Tolerance. 2014 , 327-352		4
183	Rodent models of chronic intestinal inflammation. 2001 , 241-263		2

182	Ulcerative Colitis. 2010 , 1975-2013.e9		2
181	Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. <i>Nature Microbiology</i> , 2018 , 3, 234-242	26.6	83
180	Host-microbiota interactions in inflammatory bowel disease. 2020 , 20, 411-426		133
179	Lessons for human inflammatory bowel disease from experimental models. 1999 , 15, 285-90		10
178	Galactooligosaccharide supplementation provides protection against Citrobacter rodentium-induced colitis without limiting pathogen burden. 2018 , 164, 154-162		13
177	Mutation spectrum ofNOD2reveals recessive inheritance as a main driver of Early Onset Crohn Disease.		2
176	STAT1-dependent tolerance of intestinal viral infection.		1
175	Vitamin D receptor protects against dysbiosis and tumorigenesis via the JAK/STAT pathway in intestine.		1
174	Microbiota of Mucosal Surfaces in the Gut of Monogastric Animals. 161-178		2
173	Enterohepatic Helicobacter Species. 531-548		5
172	Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. <i>Infection and Immunity</i> , 1999 , 67, 2969-74	3.7	215
171	The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease. 2001 , 107, 667-70		35
170	Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. 2003 , 111, 1297-308		197
169	Connecting the dots from Toll-like receptors to innate immune cells and inflammatory bowel disease. 2003 , 111, 1284-6		13
168	Harnessing the immune system to treat cancer. 2007 , 117, 1130-6		88
167	Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated		100
	epithelial damage in human colon explants. 2008 , 118, 1132-42		
166	Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. 2011 , 121, 4030-42		52

164	Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. 2013, 123, 4859-74	113
163	Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. 2000 , 105, 469-78	219
162	Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells. 2019 , 129, 3702-3716	63
161	Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections?. 2015 , 41, 197-203	1
160	Exploring the Molecular Basis of Host-Microbial Interactions in the GI Tract. 2002 , 21, 83-97	3
159	Microbial Factors in the Pathogenesis of IBD. 2003 , 22, 5-14	6
158	Gnotobiotic IL-10; NF-kappaB mice develop rapid and severe colitis following Campylobacter jejuni infection. 2009 , 4, e7413	34
157	Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. 2010 , 5, e13027	114
156	Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. 2013, 8, e55620	40
155	The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10-/- mice. 2013 , 8, e60270	30
154	Comparative variation within the genome of Campylobacter jejuni NCTC 11168 in human and murine hosts. 2014 , 9, e88229	23
153	Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. 2014 , 9, e94699	153
152	Association of Ulcerative Colitis with FUT2 and FUT3 Polymorphisms in Patients from Southeast China. 2016 , 11, e0146557	20
151	Sex-related Alterations of Gut Microbiota in the C57BL/6 Mouse Model of Inflammatory Bowel Disease. 2019 , 24, 173-182	18
150	Changing incidence of inflammatory bowel disease: environmental influences and lessons learnt from the South asian population. 2013 , 1, 34	18
149	Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. 2006 , 12, 4452-60	33
148	Serum interleukin-1 receptor antagonist is an early indicator of colitis onset in Galphai2-deficient mice. 2006 , 12, 621-4	8
147	Loss of CD103+ intestinal dendritic cells during colonic inflammation. 2010 , 16, 21-9	25

(2001-2011)

146	Corticotropin-releasing factor secretion from dendritic cells stimulated by commensal bacteria. 2011 , 17, 4017-22	10
145	Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. 2011 , 17, 459-69	45
144	Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis. 2013 , 19, 5347-56	15
143	Role of Salmonella enterica exposure in Chilean Crohn's disease patients. 2013 , 19, 5855-62	8
142	Use of antibiotics in the treatment of Crohn's disease. 2013 , 19, 648-53	22
141	Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice. 2014 , 20, 17084-91	11
140	Stachyose modulates gut microbiota and alleviates dextran sulfate sodium-induced acute colitis in mice. 2020 , 26, 153-159	12
139	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. 2014 , 5, 550-9	49
138	Pathogenesis of Inflammatory Bowel Diseases. 2010 , 8, 9	6
137	Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. 2012 , 10, 317	3
136	Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. 2020 , 18, 151-167	42
135	Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications. 2013 , 3, 31	7
134	Anti-Inflammatory Effects of Prunus mume Mixture in Colitis Induced by Dextran Sodium Sulfate. 2011 , 19, 16-23	9
133	The gut microbiota and gut disease. 2021 , 51, 1594-1604	2
132	The Emulsifier Carboxymethylcellulose Induces More Aggressive Colitis in Humanized Mice with Inflammatory Bowel Disease Microbiota Than Polysorbate-80. 2021 , 13,	2
131	Interleukin-10. 2000 ,	
130	Etiology and Pathogenesis of IBD ©rigins and Directions. 2001, 103-204	
129	Probiotika und Antibiotika bei chronisch entzfidlichen Darmerkrankungen (CED). 2001 , 95-100	

Role of epithelial cells in mucosal immunobiology. 2001, 55-74 128 Medical therapy for Crohn disease. 2003, 659-680 127 Inulin-Type Fructans and the Defense Functions of the Body. 2004, 126 Autoimmunity Inflammatory Bowel Disease. 2005, 525-542 125 CROHN'S DISEASE: AETIOLOGY, PATHOLOGY, DIAGNOSIS AND MEDICAL TREATMENT. 2008, 1783-1862 124 Study of the effects of dietary polyunsaturated fatty acids: Molecular mechanisms involved in 123 intestinal inflammation. 2009, 60, Microbiological Theory of Autism in Childhood. 2009, 291-311 122 Intestinal macrophage, "a double-edged sword" for homeostasis and inflammation in the gut. 2010, 121 30, 412-418 Turning on and off the Immunological Switch: Immune Response Polarization and Its Control by 120 IL-10 and STAT3. 2011, 27-55 Interaction of Probiotics with the Acquired Immune System in the Gut. 2011, 207-219 119 Intestinal Microbiota and Intestinal Disease: Inflammatory Bowel Diseases. 2012, 223-230 118 The Genetics of Inflammatory Bowel Disease. 2012, 3-16 117 116 Signal Transduction in the Intestinal Mucosa. 265-281 Role of Commensal Enteric Bacteria in Intestinal Inflammation: Lessons from Animal Models. 223-240 115 Inflammation and Colorectal Cancer. 2015, 211-256 114 Bacteriotherapy reintroduces Bld friends In IBD. 2015, 35, 122-128 113 Crohn's Disease: Clinical Manifestations and Management. 1418-1449 112 Qualitative and Quantitative Characteristics of Selected Bacterial Groups in Children with 111 Inflammatory Bowel Diseases. 2016, 65, 219-224

Immune Dysregulation Associated with Very Early-Onset Inflammatory Bowel Disease. 2017, 55-67 110 2 A gut pathobiont synergizes with the microbiota to instigate inflammatory disease marked by 109 immunoreactivity against other symbionts but not itself. Development of Inflammatory Bowel Disease is Linked to a Longitudinal Restructuring of the Gut 108 Metagenome in Mice. Bacterial Flora Play Important Roles in Acute Dextran Sulphate Sodium-Induced Colitis But Are Not 107 Involved in Gal-3 Dependent Modulation of Colon Inflammation. 2017, 18, 213-220 The labor of intestinal fence in inflammatory bowel disease. 2018, 5, 106 CHAPTER 14:Diet, Gut Microbiome and Multiple Sclerosis. 2019, 302-326 105 Body Fluid Microbiome as Cancer Biomarkers. 2019, 273-291 104 Microbes in the Pathogenesis of Inflammatory Bowel Disease: A Review. 2019, 399-410 103 Principles of Immunotherapy. 2020, 17-42 102 Physical activity shapes the intestinal microbiome and immunity of healthy mice but has no 101 protective effects against colitis in MUC2-/- mice. Microbiota Accelerates Age-Related CpG Island Methylation in Colonic Mucosa. 100 Anatomically remote education of B cells is required for colonic health. 99 Effect of Periodontopathic Bacteria Fusobacterium Nucleatum on Intestinal Im mune Cells. 2020, 98 1 18, 303-309 Development of early-stage type 1 diabetes in germ-free interleukin-10 deficient mice. 97 Inflammatory bowel diseases and innate immunity. 249-258 96 Immunomodulatory properties of the gut microflora. 103-112 95 Probiotics and inflammatory bowel disease. 281-295 94 Relevance of bacteria in the pathogenesis of inflammatory bowel disease. 21-29 93

92 Animal models in inflammatory bowel disease. 48-63

91	Loss of IL-10 signaling promotes IL-22 dependent host defenses against acute Clostridioides difficile infection.		
90	Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. 2011 , 17, 2791-800		11
89	Irritable bowel syndrome: the role of food in pathogenesis and management. 2014 , 10, 164-74		44
88	Isolation of Helicobacter spp. from mice with rectal prolapses. 2014 , 64, 171-8		15
87	Regional control of regulatory immune cells in the intestine. 2018 , 6, 29-34		2
86	Microbiome-Mediated Immune Signaling in Inflammatory Bowel Disease and Colorectal Cancer: Support From Meta-omics Data. 2021 , 9, 716604		3
85	Identification of a gut microbiota member that ameliorates DSS-induced colitis in intestinal barrier enhanced Dusp6-deficient mice. 2021 , 37, 110016		3
84	Synthetic Microbiomes on the Rise-Application in Deciphering the Role of Microbes in Host Health and Disease. 2021 , 13,		1
83	Social overcrowding impacts gut microbiota, promoting stress, inflammation, and dysglycemia. <i>Gut Microbes</i> , 2021 , 13, 2000275	8.8	3
82	Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity <i>Nature Microbiology</i> , 2022 ,	26.6	13
81	Induction and evaluation of murine colitis induced by T cell transfer <i>Methods in Cell Biology</i> , 2022 , 168, 1-17	1.8	О
80	Organoid Medicine for Inflammatory Bowel Disease Stem Cells, 2022,	5.8	1
79	Restriction of viral replication, rather than T cell immunopathology, drives lethality in MNV CR6-infected STAT1-deficient mice <i>Journal of Virology</i> , 2022 , jvi0206521	6.6	
78	The role of gut microbiome in cancer genesis and cancer prevention. <i>Health Sciences Review</i> , 2022 , 2, 100010		1
77	Network Pharmacology and Molecular Docking Analysis on Molecular Mechanism of Qingzi Zhitong Decoction in the Treatment of Ulcerative Colitis <i>Frontiers in Pharmacology</i> , 2022 , 13, 727608	5.6	Ο
76	Bio-Evaluation of the Wound Healing Activity of L. as Part of the Plant's Use in Traditional Medicine; Phytochemical, Antioxidant, Anti-Inflammatory, and Antibiofilm Properties of the Plant's Essential Oils <i>Antioxidants</i> , 2022 , 11,	7.1	7
75	The effect of a hydrolyzed protein diet on the fecal microbiota in cats with chronic enteropathy <i>Scientific Reports</i> , 2022 , 12, 2746	4.9	

(2018-2022)

74	Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022 ,	24.2	4
73	Dietary Patterns and Gut Microbiota: the Crucial Actors in Inflammatory Bowel Disease <i>Advances in Nutrition</i> , 2022 ,	10	2
72	BET Protein Inhibition Regulates Macrophage Chromatin Accessibility and Microbiota-Dependent Colitis <i>Frontiers in Immunology</i> , 2022 , 13, 856966	8.4	О
71	The Role of MIF and IL-10 as Molecular Yin-Yang in the Modulation of the Host Immune Microenvironment During Infections: African Trypanosome Infections as a Paradigm <i>Frontiers in Immunology</i> , 2022 , 13, 865395	8.4	О
70	Unravelling specific diet and gut microbial contributions to inflammatory bowel disease.		О
69	Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies <i>Biomedicine and Pharmacotherapy</i> , 2022 , 149, 112898	7.5	6
68	The Gastrointestinal Tract. 2021 , 259-283		
67	MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis <i>EBioMedicine</i> , 2021 , 74, 103751	8.8	7
66	Interleukin-10 knockout mice do not reliably exhibit macroscopic inflammation: a natural history endoscopic surveillance study.		
65	An Update of Research Animal Models of Inflammatory Bowel Disease <i>Scientific World Journal, The</i> , 2021 , 2021, 7479540	2.2	2
64	microRNA and gut microbiota: Tiny but mighty - Novel insights of their crosstalk in inflammatory bowel disease pathogenesis and therapeutics <i>Journal of Crohnus and Colitis</i> , 2021 ,	1.5	3
63	Expression of miR-29a in whole Blood of Patients with Colorectal Neoplasm. <i>Biomedical Science Letters</i> , 2021 , 27, 216-222	0.3	
62	Tissue-based IL-10 signalling in helminth infection limits IFNI expression and promotes the intestinal Th2 response <i>Mucosal Immunology</i> , 2022 ,	9.2	О
61	data_sheet_1.PDF. 2018 ,		
60	video_1.avi. 2018 ,		
59	video_2.avi. 2018 ,		
58	Data_Sheet_1.docx. 2019 ,		
57	Data_Sheet_1.docx. 2018,		

56	Image_1.jpeg. 2018 ,		
55	Image_2.tif. 2018 ,		
54	Image_3.tif. 2018 ,		
53	Table_1.docx. 2018 ,		
52	Table_2.docx. 2018 ,		
51	Data_Sheet_1.docx. 2020 ,		
50	Data_Sheet_1.docx. 2020 ,		
49	Data_Sheet_1.docx. 2018 ,		
48	Data_Sheet_1.PDF. 2019 ,		
47	Data_Sheet_1.XLSX. 2018 ,		
46	Data_Sheet_2.PDF. 2018 ,		
45	Table_1.XLSX. 2018 ,		
44	Table_2.XLSX. 2018 ,		
43	Table_3.XLSX. 2018 ,		
42	Table_4.XLSX. 2018 ,		
41	Data_Sheet_1.docx. 2019 ,		
40	How Gut Bacterial Dysbiosis Can Promote Candida albicans Overgrowth during Colonic Inflammation. <i>Microorganisms</i> , 2022 , 10, 1014	4.9	O
39	Autocrine action of IL-10 suppresses proinflammatory mediators and inflammation in the HSV-1-infected cornea. 2001 , 69, 149-157		13

38	Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012 2021: A Bibliometric Study. <i>Frontiers in Medicine</i> , 2022 , 9,	4.9	1
37	Akkermansia muciniphila plays critical roles in host health. <i>Critical Reviews in Microbiology</i> , 1-19	7.8	О
36	Dietary Eggshell Membrane Powder Improves Survival Rate and Ameliorates Gut Dysbiosis in Interleukin-10 Knockout Mice. <i>Frontiers in Nutrition</i> , 2022 , 9,	6.2	1
35	Intestine-Specific NHE3 Deletion in Adulthood Causes Microbial Dysbiosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12,	5.9	1
34	CRISPR/Cas9 Based Blockade of IL-10 Signaling Impairs Lipid and Tissue Homeostasis to Accelerate Atherosclerosis. SSRN Electronic Journal,	1	
33	Association between intestinal microbiota and inflammatory bowel disease. <i>Animal Models and Experimental Medicine</i> ,	4.2	O
32	Modulation of intestinal immune cell responses by eubiotic or dysbiotic microbiota in inflammatory bowel diseases. <i>PharmaNutrition</i> , 2022 , 21, 100303	2.9	О
31	Impact of indigenous microbiota in gut inflammatory disorders. 2022 , 179-209		
30	Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease. 2022 , 23, 9344		1
29	IL-10 Gene Rs1800871, Rs1800872, and Rs1800896 Polymorphisms and IL-10 Serum Levels Association with Pituitary Adenoma. 2022 , 10, 1921		O
28	D-Tryptophan suppresses enteric pathogen and pathobionts and prevents colitis by modulating microbial tryptophan metabolism. 2022 , 25, 104838		
27	Crohn disease in endoscopic remission, obesity, and cases of high genetic risk demonstrate overlapping shifts in the colonic mucosal-luminal interface microbiome. 2022 , 14,		О
26	The lack of transcriptionally active Nrf2 triggers colon dysfunction in female mice IThe role of estrogens. 2022 , 192, 141-151		О
25	CRISPR/Cas9 based blockade of IL-10 signaling impairs lipid and tissue homeostasis to accelerate atherosclerosis. 13,		O
24	The role of goblet cells and mucus in intestinal homeostasis.		3
23	IL-10 inhibits STAT1-dependent macrophage accumulation during microbiota-induced colitis.		1
22	Altered microbial biogeography in an innate model of colitis. 2022, 14,		0
21	Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways. 2022 , 11, 5400		2

20	Interleukin-10 Deficiency Impacts on TNF-Induced NFB Regulated Responses In Vivo. 2022, 11, 1377	O
19	Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis.	3
18	The gut microbiome in health and disease: Inflammatory bowel diseases. 2022,	0
17	Role of the E3 ubiquitin-ligase Hakai in intestinal inflammation and cancer bowel disease. 2022 , 12,	O
16	Glutamyl-prolyl-tRNA synthetase 1 coordinates early endosomal anti-inflammatory AKT signaling. 2022 , 13,	O
15	Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract.	O
14	Agr2-associated ER stress promotes adherent-invasive E. ´coli dysbiosis and triggers CD103+ dendritic cell IL-23-dependent ileocolitis. 2022 , 41, 111637	0
13	AKR1B8 deficiency drives severe DSS-induced acute colitis through invasion of luminal bacteria and activation of innate immunity. 13,	O
12	Panax notoginseng Alleviates Colitis via the Regulation of Gut Microbiota. 1-21	O
11	Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa. 1-14	O
10	Biotin Deficiency Induces Intestinal Dysbiosis Associated with an Inflammatory Bowel Disease-like Phenotype. 2023 , 15, 264	O
9	Therapeutic effect of Lactobacillus plantarum JS19 on mice with dextran sulfate sodium induced acute and chronic ulcerative colitis.	O
8	Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice. 13,	O
7	Effect of ginsenoside compound K on alleviating colitis via modulating gut microbiota. 2022 , 17,	O
6	Immune Dysregulation Associated with Very Early-Onset Inflammatory Bowel Disease. 2023, 61-74	O
5	IL-17 driven induction of Paneth cell antimicrobial functions protects the host from microbiota dysbiosis and inflammation in the ileum. 2023 ,	O
4	The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis. 2023 ,	0
3	Cross-Talk Between Gut Microbiota and Immune Cells and Its Impact on Inflammatory Diseases. 2023 , 139-162	O

Concise Commentary: An Imperfect 10Dnexpected Resolution of Spontaneous Colitis in Serially Endoscoped IL-10-/-Mice.

О

Interleukin-10 Knockout Mice Do Not Reliably Exhibit Macroscopic Inflammation: A Natural History Endoscopic Surveillance Study.

C